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Regulatory T cells (Tregs) are a small subset of immune cells that are responsible for 
downregulating the immune response and maintaining immune tolerance. Tregs are generally 
defined by a high expression of the transcription factor FOXP3. Dysfunction of Treg activity or 
number is the basis of many inflammatory diseases. Thus, there has been much research on 
understanding Treg development in the thymus and activity in the periphery and Tregs are being 
studied as a potential cellular therapy. One form of Treg therapy is generating engineered Tregs 
(eTregs), which involves expressing Treg genes in conventional T cells through retroviral or 
lentiviral transduction. The work described here investigates the role of the Ikaros family of 
transcription factors in eTreg function and thymic Treg development. The Ikaros family 
members, namely Helios and Eos, have been implicated as critical mediators of Treg induction 
and function. In the first study, we hypothesized that ectopic expression of Helios with FOXP3 is 
required for optimal engineered Treg immunosuppression. In the second study, we hypothesized 
that Ikaros family member expression correlates with Treg marker expression and defines points 
of Treg lineage commitment within CD4+ mature single positive (MSP) Tregs in the thymus. 
 In the first study, we generated eTregs by retrovirally transducing total human T cells 
with combinations of FOXP3, Helios (Hel-FL) and Δ3B Helios (Hel-Δ3B), a relevant splice 
variant of Helios. FOXP3+Hel-FL eTregs were the only eTregs able to delay disease in a 
xenogenic Graft versus Host Disease model. In vitro, FOXP3+Hel-FL CD4+ eTregs suppressed 
T cell proliferation more effectively than FOXP3 and FOXP3+Hel-Δ3B CD4+ eTregs. However, 
both FOXP3+Hel-FL CD8+ eTregs and FOXP3+Hel-Δ3B CD8+ eTregs were more effective 
than FOXP3 alone. RNA Sequencing of the CD4+ and CD8+ eTregs demonstrated that the 
addition of Hel-FL to FOXP3 in eTregs changed gene expression in cellular pathways and the 
iv 
 
Treg signature compared to FOXP3 alone or FOXP3+Hel-Δ3B. Thus, overexpression of Hel-FL 
with FOXP3 in eTregs changed gene expression in Tconvs and mediated immunosuppression in 
vivo and in vitro. Additionally, there is a functional difference between the endogenous splice 
variants of Helios in mediating CD4+ and CD8+ T cell immunosuppression.  
In the second study, we used novel CD4+ mature single positive (MSP) thymocyte 
populations that our laboratory previously defined to track CD4+ CD25+ FOXP3+ human Treg 
development from human thymus samples. We then characterized protein expression of Ikaros 
family members and Treg markers of Tregs from each of these populations. We found that a 
majority of Tregs can be found in the distinct MSP6 population and these Tregs have 
heterogenous expression of Helios and CD39 and CD127. Within the MSP1-MSP5 populations 
expression of Ikaros family members transiently changed and Helios and Eos correlated with the 
percent of Tregs within each population. Thus, using Ikaros family members and Treg markers 
within subsets of CD4+ thymocytes, we were able to more precisely determine where thymic 
Tregs originate from and critical points of Treg development. Overall, the results of this research 
provide further insight into the role of the Ikaros family members in Treg function and 
development and can be used to improve current Treg therapy. 
 
Supplemental Information: 
S1. RNA Sequencing Raw CPMs: Spreadsheet containing raw counts per million (CPMs) from 
RNA Sequencing of eTregs described in Chapter 2. FL= FOXP3+Hel-FL, d3B= FOXP3+Hel-
Δ3B. 
S2. Gene Fold Changes: Spreadsheet of top 2000 genes changed when comparing RNA 
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Chapter 1 : Introduction 
Parts of this chapter were previously published as an open access article (CC-BY) and reprinted 
here in part with adaptations. [1] Seng, A. and N. Dunavin, Mesenchymal stromal cell infusions 
for acute graft-versus-host disease: Rationale, data, and unanswered questions. ADVANCES IN 
CELL AND GENE THERAPY, 2018. 1(2): p. e14. [2] Seng, A. and T.M. Yankee, The Role of 
the Ikaros Family of Transcription Factors in Regulatory T cell Development and Function. J 
Clin Cell Immunol, 2017. 8(2).  
 
Regulatory T cells (Tregs) are a subset of immune cells that are critical for suppressing 
the immune response and promoting tolerance. There was much debate from the 1970s until the 
late 1990s whether or not there was a specific group of T cells that was solely responsible for 
suppressing immune activity. It became clear through neonatal thymectomy experiments in mice 
and rats that there was indeed a subset of T cells responsible for protecting against the 
autoimmune diseases caused by neonatal thymectomy [3, 4]. Further phenotyping experiments 
began to slowly determine surface markers that helped defined this group of suppressor cells in 
mice. These markers included CD4+, CD45RClo, CD45RBlo and CD5hi [5-9]. In 1995, Sakaguchi 
et al. determined that CD25, the alpha chain of the IL-2 receptor, was key in identifying 
suppressor T cells [10]. They demonstrated that transferring splenocytes that were depleted of 
CD25+ CD4+ T cells into T cell-deficient mice caused autoimmune disease and restoring this 
subset of T cells inhibited disease [10]. It was these key experiments that confirmed the identity 
of Tregs and led to the wide acceptance of Tregs as a novel subset of T cells. 
With surface markers available to identify Tregs and in vitro experiments to test Treg 
function, much progress has been made in investigating Treg biology. CD4+ CD25+ FOXP3hi 
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Tregs represent 3-5% of CD4+ T cells in the blood in both mice and humans [11, 12]. FOXP3 
has been shown to be a critical regulator of Treg development and activity [13-15]. Mutations in 
FOXP3 in both mice and humans result in Treg dysfunction and development of multiple 
autoimmune diseases, known as immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome in humans [16-18]. In addition, Tregs also express high levels of CD25, GITR, 
and CTLA-4, and low levels of CD127 [10, 19-21].  In humans, some activated T cells 
transiently upregulate CD25 and low levels of FOXP3 [22], making it difficult to isolate pure 
Treg populations.  A majority of Tregs are thymus-derived Tregs (tTregs), generated during T 
cell development [23-25]. Naïve T cells in the periphery can also differentiate into peripherally-
derived Tregs (pTregs) upon antigen stimulation of naïve T cells in the presence of tolerogenic 
dendritic cells and TGF-β-secreting T cells [26-28]. Within these major groups of Tregs exists 
multiple smaller subsets that differ in surface markers, transcription factor expression, cytokine 
secretion and immunosuppressive activity [29, 30].  Additionally, in vitro-induced Tregs (iTregs) 
can be generated by stimulating CD4+ T cells with various cytokines and drugs such as TGF, 
rapamycin and retinoic acid [31]. Finally, engineered Tregs (eTregs) can be produced by 
transducing CD4+ conventional T cells (Tconvs) with genes known to convey Treg activity such 
as FOXP3 [32].  Tregs can directly or indirectly suppress immune activity via a variety of 
actions. Mechanisms of Treg-mediated immune suppression include inhibiting Tconv 
proliferation and activation, secretion of immunosuppressive cytokine, killing of reactive 
immune cells and induction of anergy [33, 34]. 
Tregs play a major role in human health and disease. Impaired Treg numbers or function 
has been linked to overactive immune responses, which contributes to diseases such as 
autoimmunity, allergy, and graft-versus-host disease (GVHD) [8-10].  Conversely, tumors often 
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contain numerous Tregs that suppress anti-tumor immunity [11].  Thus, the ability to manipulate 
the number or function of Tregs could have profound therapeutic effects. In pre-clinical studies 
intravenous injection of ex vivo expanded Tregs has been used to treat murine models of multiple 
sclerosis, inflammatory bowel disease, and GVHD [12-14].  Treg adoptive transfer is currently 
being tested in clinical trials to treat GVHD, type I diabetes and transplant rejection, as well as 
other inflammatory diseases [35-39]. These trials have demonstrated the safety of Treg adoptive 
transfer therapy in humans and have had moderate success in ameliorating disease. While Treg 
therapy is promising, there are still major obstacles to overcome, including obtaining sufficient 
Treg numbers, ensuring Treg purity and maintaining Treg persistence in vivo. Gaining a better 
understanding of Treg biology will help address these limitations.  
One aspect of Treg biology that could offer insight into Treg expansion and potency is 
the role of the transcription factor Helios in Treg function.  Helios is a member of the Ikaros 
family of transcription factors that is highly expressed in 70% of human Tregs [25]. All T cells in 
both mice and humans express two isoforms of Helios, a full length form (Hel-FL) and shorter 
isoform lacking half of the 3rd exon (Hel-Δ3B) [40, 41].  Treg specific knock-out of total Helios 
in mice results in development of spontaneous autoimmunity at 6-8 months of age, decreased 
Treg immunosuppressive function, secretion of pro-inflammatory cytokines, and survival [42, 
43]. In humans, knock down of Helios in Tregs via siRNA resulted in reduced suppressive 
activity and reduced FOXP3 expression [44]. Helios-positive (Helios+) Tregs more effectively 
suppress cytokine secretion by pro-inflammatory T cells in vitro compared with their Helios-
counterparts in both mice and humans [25, 45-48].  Thus, Helios is a key mediator of Treg 
activity in both mice and humans. However, how Helios functions to enhance Treg function has 
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not been delineated. The aim of the work described in this dissertation was to determine the 
effect of endogenous Helios splice variants on human Treg development and function. 
 
Origin of Tregs 
Thymic Treg development 
Approximately 70% of circulating Tregs are generated in the thymus during T cell 
development [23-25]. The mechanisms for human Treg commitment in the thymus are largely 
unknown as well as when this commitment step takes place. Understanding Treg development is 
crucial, as inherent Treg dysfunction or reduced Treg numbers is the basis for many autoimmune 
diseases including inflammatory bowel disease (IBD), Type I diabetes and myasthenia gravis 
[49-55]. Additionally, there are currently no accepted markers that can be used to distinguish 
human tTreg from pTregs in the periphery.  Characterization of the developmental pathway 
leading to tTregs could also lead to the identification of such markers. 
The complete mechanism of tTreg commitment in the thymus is unclear, but T cell 
receptor (TCR) signal strength, co-stimulation and cytokine stimulation are major mediators [56, 
57]. In mice, it has been established that Treg development requires a strong interaction of the  
TCR with its cognate self-antigen presented by thymic epithelial cells (TECs) or antigen 
presenting cells (APCs) [58, 59]. TCR signaling in human Treg development can only be 
indirectly tested, but expression of positive selection markers, including CD69 and CD27, are 
upregulated on developing Tregs [60-64]. Another indication of TCR engagement in human Treg 
development is the expression of CTLA-4 in DP and CD4+ SP tTregs [63, 65, 66]. Additionally, 
patients deficient in ZAP-70, a key regulator of T cell signaling, have reduced numbers of 
developing Tregs in the thymus [67]. Expression of FOXP3 can be induced by TCR engagement 
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as a result of  binding sites for NFAT and AP-1 in the FOXP3 promoter, which are both 
downstream targets of TCR signaling [68]. In addition to TCR signaling, various co-stimulation 
pathways are upregulated in Treg development through interaction with TECs or dendritic cells 
(DCs) including JAK3/STAT-5, Notch, CD80/CD86, ICOS/ICOSL and CD40/CD40L [69-71]. 
Finally, IL-2 and IL-15 stimulation is important in maintaining tTreg proliferation and survival 
during development [72, 73]. DCs and other thymocytes are likely the sources of IL-2 and B 
cells, macrophages and TECs have been identified as the primary sources of IL-15 in the thymus 
[72]. 
With the limited Treg markers that are available, namely FOXP3 and CD25, it has thus 
far been concluded that human Treg lineage commitment can occur at CD4+ CD8+ double 
positive (DP) and CD4+ single positive (SP) developmental stages [56]. In general, commitment 
of FOXP3+ DP cells to the Treg lineage is thought to be driven by interaction of progenitor 
Tregs with cortical TECs and macrophages via TCR followed by stimulation by IL-2 and IL-15 
[63, 70, 72]. FOXP3+ DP cells can differentiate into FOXP3+ CD4+ SP tTregs or FOXP3+ 
CD8+ SP tTregs. CD103+ FOXP3+ DP cells are likely the subset that differentiates into CD8+ 
SP tTregs as CD4+ SP tTregs do not express high levels of CD103. Alternatively, mature 
FOXP3- CD25- CD4+ SP in the medulla can acquire FOXP3 and CD25 expression through 
various combinations of TCR engagement with mTECs or APCs presenting tissue-specific self-
antigens, activation of co-stimulatory pathways and IL-2 and IL-15 stimulation [69, 72, 74, 75]. 
The exact path that thymocytes follow to Treg lineage commitment can be further elucidated 
using other Treg markers.  
Our laboratory defined novel subsets of human thymocytes using multi-parameter flow 
cytometry with the goal of identifying the sites at which the major T cell developmental 
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checkpoints occur [2, 76, 77].  Human thymocytes were isolated from discarded thymus from 
pediatric cardiac surgery patients. The first novel subset is the immature single positive (ISP) 
CD4+ population. Consistent with previous reports [78-82], we found that in about half of 
patients, CD4-CD8- double negative (DN) thymocytes differentiate into ISP CD4+ thymocytes 
before expressing CD8 to become CD4+CD8+ double positive (DP) thymocytes [76].  In the 
other half of patients, CD4 and CD8 are expressed simultaneously, resulting in few ISP CD4+ 
cells.  In a few rare cases, an ISP CD8+ population is present where CD8 is expressed prior to 
CD4.  In some cells, expression of TCR occurs during the ISP CD4+ stages, which a critical 
step in DN to DP transition. Other cells do not express TCR until the early DP stages. After  
selection, we found that DP thymocytes decrease their CD4 expression to become transitional 
single positive (TSP) CD8+ thymocytes [77].  Positive selection occurs in the TSP CD8+ 
developmental stage.  In addition, the initial steps towards CD4/CD8 lineage commitment begin 
in the TSP CD8+ stage.  Cells destined to become mature CD8+ thymocytes continue to down-
regulate CD4 and remain CD8+.  Cells destined to become mature CD4+ thymocytes express 
CD4 to return to the CD4+CD8+ DP population before down-regulating CD8 [77].  
To identify where Tregs emerge within our newly defined subsets of T cell development, 
we initially analyzed CD25 and FOXP3 expression.  These markers were first detected in post-
selection DP thymocytes that are newly committed to the CD4+ T cell lineage.  Additionally, 
CD25hi FOXP3hi cells were found in the mature CD4+ SP population. Because all tTregs 
express Helios, we added the analysis of Helios expression to FOXP3 and CD25 to facilitate the 
identification of developing Tregs [77].  Among mature CD3hiCD4+ thymocytes, Helios was 
only highly expressed in cells that also expressed FOXP3 and CD25. Helios+ FOXP3+ CD25+ 
thymocytes could also be found within the DP population, specifically among cells that had 
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already undergone positive selection.  These cells were between the TSP CD8+ thymocyte stage 
and the mature SP CD4+ stage, indicating that these cells are in the process of committing to the 
SP CD4+ lineage [77].  Thus, using this combination of markers, we could trace to the 
developmental stages in which commitment to the CD4+ T cell lineage occurs.  Independently of 
FOXP3 and CD25, Helios was also expressed in subsets of TSP CD8+ thymocytes [77].  At this 
stage, Helios might mark the earliest Treg population or thymocytes undergoing negative 
selection [83]. My dissertation work further expands on this research by correlating expression of 
Treg markers to Ikaros family members during the development of mature SP CD4+ thymocytes. 
 
Differentiation of peripheral Tregs  
In addition to tTregs that develop in the thymus, naïve CD4+ CD25- FOXP3- T cells can 
differentiate into peripherally-derived Tregs (pTreg) cells upon recognition of cognate antigen 
under tolerogenic conditions [26]. It is difficult to study human pTreg generation as there are no 
accepted markers that distinguish pTregs from tTregs. However, in mice, lineage tracing 
experiments can be used to track Foxp3- CD4+ cells that upregulate Foxp3 upon differentiation 
into pTregs [84]. Through these studies, the types of antigens and the conditions needed to 
promote pTreg differentiation have been established. Analysis of the TCR specificity of murine 
pTregs revealed that generally recognize non-self antigen [84-91]. Chronic exposure of mice to 
low levels of foreign peptides via oral or intranasal routes can also increase the number of pTregs 
[27, 92-95]. Thus, the source of non-self antigens can come from environmental exposure to 
food or allergens. An additional source of pTreg cognate antigen is commensal bacteria [90, 96, 
97]. Lathrop et al. [90] reported that murine pTregs isolated from the colon had a different TCR 
repertoire compared to other Tregs isolated from the periphery. Most of these TCRs recognized 
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antigens derived from commensal bacteria. Additionally, a specialized subset of CD103+ DCs in 
the mesenteric lymph nodes of mice was identified to be critical in pTreg generation in the gut 
[98]. Analysis of Treg TCR repertoire from both the thymus and peripheral blood in humans has 
revealed that CD25+ CD4+ Tregs have a similar diversity as CD25- CD4+ Tconvs [99]. 
Additionally, Tregs targeting allergens have been isolated from human peripheral blood and a 
commensal bacteria-derived molecule was able to induce human Tregs in vitro [100, 101]. Thus, 
pTregs that recognize non-self antigens could potentially exist in humans as well as mice. Naïve 
CD4+ T cells can differentiate into pTregs through recognition of cognate non-self antigen under 
non-inflammatory conditions.  
Various soluble mediators of pTreg differentiation have also been identified. In both 
mouse and humans, the secretion of the cytokine TGFβ by dendritic cells is critical for pTreg 
differentiation [28, 102-105]. In mice, CD8+ CD205+ splenic DCs in peripheral lymphoid 
tissues and CD103+ DCs in the mesenteric lymph nodes are the primary sources of TGFβ during 
pTreg generation [98, 104, 106, 107]. TGFβ promotes survival of pTregs and directly drives 
FOXP3 expression in naïve CD4+ Tregs through downstream recruitment of the transcription 
factors Smad3 and NFAT to the FOXP3 promoter [89, 108]. Additionally, TGFβ maintains Treg 
phenotypic stability by opposing recruitment of DNA methyltransferase 1 (Dnmt1) to the 
conserved non-coding sequence 2 (CNS2) region of the FOXP3 gene locus [109]. CNS2 contains 
the Treg-specific demethylated region (TSDR) which needs to remain unmethylated to enhance 
FOXP3 expression [110, 111]. In the gut, retinoic acid secretion by DCs is required in addition 
to TGFβ to convert naïve CD4+ T cells to pTregs in response to commensal bacteria antigens 
[98]. Retinoic acid directly induces FOXP3 expression in pTregs and also blocks conversion of 
naïve CD4+ T cells to other Th subsets [112-115]. IL-2 is another cytokine required for 
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differentiation of naïve CD4+ T cells to pTreg. IL-2 not only supports pTreg growth and survival 
but directly opposes signals for Type 17 helper (Th17) cell differentiation [116, 117]. Naïve 
CD4+ T cell conversion to a Th17 cell requires TCR stimulation in the presence of TGFβ, 
similar to pTreg differentiation, and differs in the additional requirement of IL-6 [118]. IL-2 
activation of STAT5 directly constrains Th17 differentiation [116]. The combination of TGFβ, 
retinoic acid and IL-2 is able to convert naïve human CD4+ T cells into functional in vitro 
induced Tregs (iTregs) [119, 120]. Thus, TGFβ, retinoic acid and IL-2 are critical for inducing 
and promoting the survival of pTregs. 
In addition to TCR stimulation and cytokines, direct interaction of naïve CD4+ T cells 
with costimulatory molecules on APCs is important in pTreg differentiation. The signals that 
promote a pTreg phenotype would normally be inhibitory to a Tconv. For example, CTLA-4 is 
normally expressed on activated Tconv and binds CD80 or CD86 on APCs which leads to 
downregulation of pro-inflammatory pathways [121, 122]. Conversely, CTLA-4 is required for 
TGFβ-mediated pTreg differentiation and CTLA-4/CD80 interaction after TCR activation aids in 
FOXP3 expression after TGFβ stimulation [123]. Another critical costimulatory pathway 
involved in pTreg differentiation is CD28 activation. In the differentiation of naïve CD4+ T cells 
into pro-inflammatory Tconv, CD28 binding to B7 proteins on APCs is one of the primary 
“second signal” interactions required for the T cell to differentiate and become fully activated 
[124, 125]. In pTreg differentiation, CD28 activation is detrimental to pTreg generation [104, 
126]. Overall, pTregs make up a unique subset of Tregs that have a TCR repertoire that 





 Upon stimulation, naïve CD4+ T cells have the potential to differentiate into multiple 
helper T (Th) cell subsets depending on co-stimulatory signals and cytokine stimulation. Each Th 
subset has a specific lineage defining transcription factor that drives specific functions and 
cytokine secretion [127]. Activated T cells then proliferate, migrate to distant sites depending on 
chemokine receptor expression and mediate an immune response. Activated T cells have the 
potential to differentiate into memory T cells which become re-activated upon subsequent 
exposure to the same cognate antigen [128]. While Tregs are often thought as one small subset of 
CD4+ T cells, they are a very heterogenous population. Under various conditions, Tregs can 
adopt different patterns of gene expression that modulate function and localization. Similar to 
Tconvs, naïve Tregs can become memory Tregs following activation [129-133]. Additionally, 
there are Treg subsets that express similar transcription factors and cytokines as other Th subsets 
[29, 134-138]. There are also groups of CD4+ T cells that do not express FOXP3 but are able to 
suppress via suppressive cytokine secretion [139-141]. Finally, there are also CD8+ Tregs that 
are primarily thymus-derived [43, 56, 142, 143]. The following sections will describe each of 
these Treg subsets in depth.   
 
Naïve vs Memory Tregs 
 In both mice and humans, after TCR stimulation, naïve T cells become activated and lose 
CD45RA expression and gain CD45RO expression, a marker of effector or memory T cells 
depending on the co-expression of other surface markers [144]. Multiple studies have identified 
and characterized CD45RA+ and CD45RO+ Tregs in humans and termed these populations as 
naïve and memory Tregs [139-141]. Naïve Tregs are primarily derived from the thymus as the 
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majority of these cells express CD31, a marker of recent thymic emigration [132]. A majority of 
Tregs in humans are CD45RO+ [145]. Upon activation, CD45RA+ Tregs lose CD45RA 
expression and gain CD45RO+ expression [132, 133]. There is also evidence that FOXP3- 
Tconvs can also gain a memory Treg phenotype [132]. Both populations suppress responder T 
cell proliferation to a similar degree in vitro but also differ in immunosuppressive mechanisms. 
Naïve Tregs expressed higher levels of CXCR4 which localizes these cells to the bone marrow. 
On the other hand, memory Tregs have higher CCR4 and cutaneous lymphocyte antigen (CLA) 
expression which drives migration primarily to the skin [132]. Another difference between naïve 
and memory Tregs is their proliferative potential. Under homeostatic conditions, memory Tregs 
undergo a higher rate of proliferation than naïve Tregs [132, 133]. During co-culture with 
Tconvs in a suppression assay, naïve Tregs are activated and proliferate whereas memory Tregs 
undergo a higher rate of cell death, likely due to activation induced cell death [133]. This 
proliferation of memory Tregs is thought to be the primary source of new Tregs in humans as the 
thymus involutes during aging. In fact, older adults have a higher percentage of memory Tregs 
compared to naïve Tregs [132]. Thus, upon activation, naïve Tregs from the thymus differentiate 
into memory Tregs resulting in a change in gene expression and function.  
 
Thelper subsets  
 Under different inflammatory conditions, naïve CD4+ Tconvs differentiate into various 
Thelper (Th) subsets with specialized functions [127]. The most common subsets are Type 1 
helper (Th1), Type 2 helper (Th2), Type 17 helper (Th17) cells and T follicular helper (Tfh) cells 
and each has a lineage specific transcription factor that drives subset-specific function. Th1 cells 
express Tbet and target intracellular pathogens [146, 147], Th2 cells express GATA3 and are 
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responsible for killing parasites and mediate allergic reactions [146, 147], Th17 cells express 
RORγt and are specialized to clear fungal infections [147, 148] and Tfh cells express Bcl6 and 
mediate B cell maturation in germinal centers [149]. The Thelper subsets also express specific 
chemokine receptors and cytokines to localize cells to specific tissues and mediate a specialized 
immune response [150-156]. Duhen et al. [29] stained human Tregs for the chemokine receptors 
that distinguish the different Thelper subsets and FACS sorted the Tregs based on the pattern of 
chemokine receptor expression. Interestingly, there was a corresponding Treg for each Th 
population based on chemokine receptor expression. Specifically, Th1, Th2, Th17 and Th22-like 
Tregs were identified. Furthermore, these Th-like Treg subsets co-expressed FOXP3 with each 
Th lineage-specific transcription factor and had similar cytokine secretion profiles. Despite 
secretion of pro-inflammatory cytokines, each Treg subset was able to suppress proliferation of 
responder Tconvs in vitro [29]. Additional studies have identified Tregs that specifically target 
Tfh cells and express similar chemokine receptors and transcription factors [134, 157].  While 
production of pro-inflammatory cytokines does not affect in vitro suppression by these Treg 
subsets, they could affect Treg function in vivo. For example, a higher level of IL-17 producing 
Tregs have been identified in the mucosal tissue of patients with Crohn’s disease compared to 
healthy patients [158]. While these IL-17-producing Tregs remain suppressive in vitro, IL-17 has 
been demonstrated to drive Crohn’s disease pathogenesis, though it is unclear whether or not 
these Tregs are beneficial or detrimental to disease [158, 159].  Thus, under different 
inflammatory conditions, Tregs can also acquire specialized functions to better target different 
Th CD4+ subsets and mediate downregulation of inflammation. However, the secretion of pro-
inflammatory cytokines by these Treg subsets can also exacerbate disease.    
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Tr1 and Th3 cells 
 In addition to Treg subsets that mimic Tconv subsets, there are unique subpopulations of 
Tregs that can develop from naïve CD4+ T cells in the periphery under specific cytokine 
stimulation. Interestingly, these subsets are able to suppress inflammation despite a lack of 
FOXP3 expression. Type 1 regulatory (Tr1) cells develop through TCR stimulation in the 
presence of high levels of IL-10 and Th3 cells develop in the presence of TGFβ [160, 161]. DCs 
are the primary source of IL-10 and TGFβ in the generation of Tr1 and Th3 cells respectively 
[162, 163]. Tr1 cells were first identified and characterized in OVA-specific TCR transgenic 
mice through repeated stimulation of T cells with OVA in the presence of IL-10 [140]. Th3 cells 
were identified in mice after induction of oral tolerance to myelin basic protein (MBP). In this 
model, Th3 cells were able to suppress MBP-specific Th1 cells via production of TGFβ [141]. 
Both Tr1 cells and Th3 cells upregulate expression of CTLA-4 and CD25, classical markers of 
Tregs [139, 160, 161]. Expression of integrin α4β1mediates migration of Tr1 cells to the 
endothelium of inflamed peripheral tissue, whereas Th3 cells express integrin α4β7, also known 
as CD103, and localize to mucosal tissues [139]. Tr1 cells primarily mediate immunosuppression 
via secretion of IL-10, a generally inhibitory cytokine. Th3 regulate the immune response 
through secretion of TGFβ which can drive conversion of naïve T cells into FOXP3+ pTregs as 
described previously, a phenomenon known as infectious tolerance or the bystander effect [164]. 
Both cells can also alter DC stimulation of T cells, indirectly reducing inflammation [139, 164].  
Tr1 cells have been identified in humans and tested as a potential cell therapy in inflammatory 
bowel disease [165, 166]. Th3 cells have yet to be identified in humans but human iTregs can be 
induced by stimulation of naïve CD4+ T cells in the presence of TGFβ in addition to IL-2 and 
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retinoic acid [119, 120]. Thus, Tr1 and Th3 cells can develop in the periphery aid in immune 
regulation along with tTregs and FOXP3+ pTregs.  
 
CD8+ Tregs 
 Treg research has primarily been focused on CD4+ Tregs but CD8+ Tregs also exist and 
were first identified in 1970 by Gershon and Kondo [167]. CD8+ Tregs have been difficult to 
study until recently due to a lack of defined markers to distinguish them from conventional 
CD8+ T cells. CD8+ Tregs in mice are CD8+, Ly49+, CD122+ and CD44+ [143, 168] and in 
humans, the predominant CD8+ Treg subset that has been described is CD8+, CD28- [169, 170]. 
Additional markers of human CD8+ Tregs include upregulation of CD25, CD122, CD45RO 
and/or CCR7[171]. In addition to these surface markers, FOXP3+ and FOXP3- CD8+ Tregs also 
exist. As previously described, FOXP3+ CD8+ Tregs develop from DP thymocytes. The TCR’s 
on most CD8+ Tregs are restricted to a non-classical MHC Ib molecule called Qa-1 in mice 
[172, 173] and HLA-E in humans [174-176]. This section will focus on the Qa-1/HLA-E 
restricted FOXP3+ CD8+ Tregs, which are the most well characterized CD8+ Treg population. 
Under homeostatic conditions, Qa-1/HLA-E presents peptides derived from the signal sequence 
of classical MHCI [177]. During stress or under abnormal antigen processing conditions such as 
cancer, loading of MHCI peptide onto Qa-1/HLA-E is disrupted and presentation of a different 
peptide results in CD8+ Treg stimulation via TCR [178-183]. The Qa-1/HLA-E-peptide complex 
can bind TCR or NKG2A/CD94, a set of receptors expressed by natural killer (NK) cells [184, 
185]. Qa-1 knock out mouse experiments demonstrated the importance of Qa-1-peptide-TCR 
interaction in CD8+ Treg development, as these mice developed severe autoimmune disease 
[168, 186, 187]. Additionally, in humans, CD8+ Tregs have been identified in the tumor 
15 
 
microenvironment and act as mediators of tumor immune evasion [188-190]. CD8+ Tregs 
regulate the immune response through direct mechanisms such as cytolysis of CD4+ T cells, 
cell-cell contact via inhibitory co-receptors such as CTLA-4, and indirect actions such as 
modifying DC expression of costimulatory molecules and inhibitory cytokine secretion [168, 
191, 192]. CD8+ Tregs are primarily found in mucosal tissues and rarely found in the blood [56]. 
Thus, CD8+ Tregs as well as CD4+ Tregs play a major role in immune regulation and human 
disease.  
 
Treg Phenotype Stability 
With the ability of Treg subsets to acquire the ability to secrete pro-inflammatory 
cytokines under certain inflammatory conditions, the question has arisen if Tregs can lose their 
immunosuppressive capacity. The primary regulators of Treg function are FOXP3 expression 
and epigenetic modifications within the Treg genome, which will be discussed in detail in later 
sections. If any of these factors are lost, Tregs have a higher potential of converting into a pro-
inflammatory phenotype. There has been much debate over the stability of the Treg phenotype. 
This question has primarily been addressed in Treg lineage tracing assays in mice. These assays 
use FOXP3-GFP mice that express a FOXP3 driven Cre that cleaves the stop codon out of a 
Rosa-LSL-YFP or a ROSA-LSL-RFP reporter. Thus, any cells that express FOXP3 would be 
GFP+ and YFP+/RFP+ but upon loss of FOXP3, cells would be GFP- YFP+/RFP+. One 
experiment by Zhou et al. [193], determined that a small subset of CD4+ FOXP3+ T cells lost 
FOXP3 expression under lymphopenic or inflammatory conditions and these cells were termed 
“exTregs.” Furthermore, when these exTregs were transferred into mice, they caused 
autoimmunity [193]. Interestingly, exTregs were able to regain FOXP3 expression after 
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inflammation was resolved or IL-2 was administered [194]. However, another experiment by 
Rubtsov et al. [195] that integrated GFP into the FOXP3 locus rather than using FOXP3-GFP 
expressed on an artificial chromosome and used a conditional Cre that was induced by tamoxifen 
exposure. They found that FOXP3+ Tregs were stable and 96% of the cells maintained FOXP3 
expression under lymphopenic and inflammatory conditions [195].  
To reconcile these differences, Miyao et al. [196] repeated these experiments and also 
integrated GFP into the chromosome and used a ROSA-LSL-RFP reporter. They found that there 
was indeed a group of GFP- RFP+ cells that lost FOXP3 expression. However, they determined 
that these cells were actually FOXP3- cells that transiently upregulated FOXP3 and then lost 
FOXP3 expression. These cells were RFPlo, CD25lo and GFP+ prior to losing FOXP3 
expression [196]. The differences in these experiments may have been due to the timing of the 
FOXP3 labeling as Zhou et al. and Miyao et al. labeled FOXP3+ cells from the start and Miyao 
et al. labeled FOXP3 at a certain timepoint with the addition of tamoxifen. It is likely that more 
exTregs were observed in the experiments performed by Zhou et al. and Miyao et al. because 
there was a longer time frame to label the cells expressing low levels of FOXP3 or unstably 
expressing FOXP3. On the other hand, the cells that were GFP+ in Rubtsov et al. were likely 
committed Tregs that were stably expressing FOXP3. The idea that not all FOXP3+ cells are 
committed to a Treg phenotype is termed the “heterogeneity model” [197, 198]. This is evident 
in humans as Tconvs can acquire transient low FOXP3+ expression following stimulation [133, 
199, 200]. Despite the debate over the origin of the exTregs, it clear that in mice, there is a subset 
of FOXP3+ cells that lose FOXP3 expression under lymphopenic and inflammatory conditions. 
Furthermore, these exTregs are able to cause disease [193]. In humans, CD4+ CD25hi CD127lo 
FOXP3+ Tregs can lose FOXP3 expression after multiple TCR stimulations in vitro and memory 
17 
 
Tregs have been shown to lose FOXP3 expression after long term expansion in vitro [133, 201, 
202]. The potential of Tregs converting into autoreactive Tconvs is of great concern especially in 
the field of Treg immunotherapy. Thus, it is critical to elucidate the factors required to identify 
uncommitted FOXP3+ cells and maintaining Treg stability. 
 
Mechanisms of Treg-mediated immunosuppression 
Tregs mediate immune homeostasis through suppression of multiple aspects of immune 
activity including Tconv proliferation and cytokine secretion, expression of costimulatory 
molecules and antigen presentation by APCs [33]. Different Treg functions have generally been 
elucidated via in vitro suppression assays where Tregs are co-cultured with responder Tconvs 
and proliferation of Tconvs is assayed following stimulation. However, the context of Treg 
function has proven to be important as mechanisms that were identified as not critical for in vitro 
suppression have been shown to be necessary in various murine models of inflammatory 
diseases. This section will focus on the direct and indirect mechanisms of Treg-mediated 
immune suppression that target Tconv and APCs that have been identified in in vitro and in vivo 
assays.   
 
Treg suppression of Tconv 
 Tregs can directly suppress proliferation and function of Tconvs following stimulation in 
vitro. The primary effect of Treg suppression is a reduction of Tconv IL-2 production, a key T 
cell growth factor as well as other pro-inflammatory cytokines such as IFNγ  [203-207]. 
Reduction of IL-2 mRNA in Tconv after co-culture with Tregs in vitro has been observed in both 
murine and human cells [203-206]. How Tregs mediate reduce IL-2 production by responder T 
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cells is largely unknown, but in vitro, cell-cell contact is required [204, 206, 208]. Schmidt et al. 
[209] demonstrated that following co-culture of Tconv and pre-activated Tregs in vitro, there 
was a decrease in calcium influx following TCR stimulation in Tconvs. This decrease in calcium 
influx reduced downstream NFAT and NFκB activity and directly inhibited cytokine 
transcription. The exact mechanism of Treg-mediated reduction in Tconv calcium signaling has 
yet to be elucidated. Tregs can also compete with Tconvs for IL-2 via high expression of the IL-2 
receptor alpha chain (CD25) and expression of the other IL-2 receptor components [205, 210]. 
Pandiyan et al. [211] demonstrated that Treg-mediated cytokine starvation led to apoptosis of 
Tconv. This mechanism of Treg suppression has been controversial as multiple studies did not 
observe apoptosis in Tconvs following Treg co-culture in both human and murine cells [207, 
212, 213]. Additionally, blocking CD25 on human Tregs did not reduce Treg-mediated 
suppression of mouse Tconvs and adding IL-2 only partially reduced Tconvs suppression by 
Tregs [207, 214]. While Tregs likely compete with Tconvs for IL-2, this is not likely the primary 
mechanism of Treg immunosuppression. Thus, changing the cytokine milieu is a critical 
mechanism of Treg activity. 
 In addition to affecting availability of cytokines, Tregs can also block Tconv activity 
through secretion of inhibitory cytokines. The primary Treg inhibitory cytokines that have been 
identified are TGFβ, IL-10 and IL-35. TGFβ predominately acts to convert Tconv to Tregs in the 
presence of DCs as previously described [214, 215]. TGFβ can also act to suppress proliferation 
and cytokine secretion in Tconvs [216]. The importance of TGFβ in Treg-mediated suppression 
is controversial. The role of TGFβ in maintaining tolerance is evident in the fact that TGFβ or 
TGFβ receptor KO mice develop autoimmunity [217, 218]. However, TGFβ-deficient Tregs can 
still suppress Tconv proliferation in vitro [219, 220]. Interestingly, TGFβ production by Tregs is 
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necessary to suppress colitis in vivo [219, 220].Thus, the importance of TGFβ in suppressing 
inflammation may depend on the disease. IL-10 is a predominately inhibitory cytokine but can 
be pro-inflammatory at different concentrations and cell contexts [221, 222]. Tconvs treated with 
IL-10 in vitro have reduced cytokine secretion [222] and naïve Tconv can be converted to IL-10 
secreting Tr1 cells in the presence of IL-10 during TCR stimulation [165]. IL-10 is specifically 
important in preventing gut inflammation as IL-10 KO mice spontaneously develop colitis [223]. 
Treg production of IL-10 is important in the suppression of multiple CD4+ Th subsets including 
Th17 cells and Th1 cells [224, 225]. IL-35 is a cytokine that is made up of Epstein-Barr virus 
induced gene 3 (Ebi3) and IL12a [226]. IL-35 KO Tregs have reduced suppression in vitro and 
in vivo in a murine colitis model [227]. Human Tregs do not normally make a high level of IL-35 
but IL-35 production can be induced by iTregs in vitro [203]. Treg secretion of inhibitory 
cytokines plays a key role in inhibiting Tconv proliferation and activation.  
 While many Treg functions are mediated through soluble mediators, Tregs can also 
directly interact with Tconv through cell-cell contact. One inhibitory surface molecule that 
mediates direct contact between Tregs and Tconvs is Galectin-1, a β-galactoside-binding protein 
[228]. Galectin-1 is upregulated on Tregs upon TCR stimulation and binds ligand on Tconvs 
which leads to cell cycle arrest, apoptosis and reduced cytokine secretion. Blocking Galectin-1 
reduces Treg suppression in both human and mice [228]. In addition to direct inhibition through 
surface molecules, both human and murine Tregs can directly kill Tconvs via perforin activity 
and granzyme secretion [229, 230]. In murine tumor models, approximately 5-30% of Tregs 
expressed granzyme B and these Tregs could kill NK and CD8+ T cells [231]. Thus, direct 




Treg suppression of APCs 
 Tregs can indirectly suppress Tconvs through interactions with APCs. Tregs have several 
surface molecules that interact with APCs and reduce APC activation of Tconv. This section will 
focus on the activity of CTLA-4, LAG-3 and Nrp-1. CTLA-4 deficiency or blockade in mice 
leads to autoimmunity that is reversed upon transfer of wild-type Tregs [20, 232]. Human Tregs 
require CTLA-4 to suppress APC-mediated Tconv proliferation in vitro [209]. Binding of 
CTLA-4 to CD80/CD86 on DCs leads to downregulation of these costimulatory molecules. The 
lack of costimulation following CTLA-4 binding of DCs inhibits Tconv activation both in vitro 
and in vivo [233-235]. CTLA-4 stimulation also leads to indoleamine 2,3-dioxygenase (IDO) 
secretion by DCs which acts to suppress Tconv proliferation [236, 237]. LAG-3 is another 
inhibitory surface protein that is upregulated on Tregs. Binding of LAG-3 to MHCII on DCs 
inhibits DC activation and maturation leading to decreased antigen presentation [238, 239]. Treg 
expression of neuropilin-1 (Nrp-1) promotes Treg interaction with immature DCs, allowing for 
prolonged suppression and reduces antigen presentation by APCs [240, 241]. Blocking Nrp-1 in 
vitro reduces suppression when Tconvs are stimulation with low amounts of antigen [240]. 
Direct interaction of Tregs with APCs plays a major role in reducing Tconv activation via TCR-
MHCII stimulation and co-stimulation.  
 In addition to inhibitory surface molecules, Treg TCR’s can also recognize cognate 
peptide presented on MHCII on APCs. The role of antigen specificity in Treg function is under 
constant debate. Polyclonal Tregs can suppress a murine model of experimental autoimmune 
encephalitis (EAE) and OVA-specific diabetes by blocking proliferation of effector T cells in 
lymph nodes [242, 243]. It is thought that polyclonal Tregs do not require TCR stimulation to 
mediate suppression. However, there is evidence that antigen-specific Tregs are more potent than 
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polyclonal Tregs at suppressing autoimmunity in vivo [244, 245]. Multiple studies used two 
photon laser scanning to investigate interaction of antigen-specific Tregs with APCs and Tconvs 
[246, 247]. These studies demonstrated that antigen-specific Tregs had longer interactions with 
naïve antigen-loaded DCs and reduced antigen-specific Tconv-DC interactions. These 
interactions led to reduced cytokine production by Tconvs. Interestingly, there was no evidence 
of direct Treg-Teff interactions, indicating that in vivo, Tregs primarily target DCs. A recent 
publication by Akkaya et al. [248] expanded on these observations and demonstrated that 
antigen-specific Tregs were binding DCs via TCR-MHCII binding and removing MHCII-peptide 
complexes through a process known as trogocytosis. This novel Treg mechanism reduces APC 
presentation of antigens to Tconv and subsequent activation. Thus, while polyclonal Tregs are 
able to inhibit the immune response in vitro and in vivo, antigen-specific Tregs have a unique set 
of immunosuppressive properties that make them more potent than polyclonal Tregs.   
 Finally, Tregs also use soluble mediators to suppress APCs. IL-10 not only directly 
reduces Tconv proliferation and cytokine production but also acts to downregulate costimulatory 
molecule expression on APCs [165]. Additionally, 50% of human Tregs express a pair of surface 
ectonucleases, CD39 and CD73, that together cleave extracellular ATP into adenosine [249-252]. 
Adenosine binds the A2A on DCs and decreases costimulation by APCs [253, 254]. CD39-
deficient Tregs have reduced suppressive capacity [252]. Tregs utilize multiple soluble 
molecules to inhibit APC stimulation and activation of Tconvs.  
   
FOXP3 and Tregs 
A hallmark of Tregs is high expression of the transcription factor FOXP3. FOXP3 is 
necessary for Treg-mediated immune homeostasis, as mice and humans deficient in FOXP3 
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develop severe autoimmune diseases[17, 18]. Ectopic expression of FOXP3 in both murine and 
human CD4+ Tconvs conveys a Treg phenotype including reduced cytokine production and 
slowed proliferation. Furthermore, these FOXP3 overexpressing cells were able to suppress 
responder T cell activity in vitro and in vivo [14, 32, 255]. Thus, FOXP3 not only defines Tregs 
in both mice and humans but is the key transcription factor in driving Treg activity.  
 
Structure and downstream signaling 
 FOXP3 is a member of the subfamily P of the FOX protein family [256]. Members of the 
FOX protein family all have a forkhead/winged helix DNA binding region [257]. Other 
structural features of FOXP3 include a central domain in the C terminus, which contains a C2H2 
zinc finger and leucine zipper, and a repressor domain in the N-terminus [258, 259]. FOXP3 
primarily mediates transcriptional regulation through interaction with other transcription factors. 
The forkhead domain of FOXP3 binds the target sequence of AP-1, a downstream transcription 
factor that is activated with TCR signaling. Consequently, binding of FOXP3 to this sequence 
blocks AP-1-NFAT interaction and inhibits T cell activation [260]. FOXP3 alters T cell 
transcription through formation of oligomers with other transcription factors via the zinc finger 
and leucine zipper domains [261]. For example, FOXP3 binding of DNA with NFAT is required 
for repression of Il2, Ctla-4 and Cd25 transcripts and Treg suppressive activity [260]. Binding of 
FOXP3 via the leucine zipper to the AML1/Runx1 complex is also critical for suppression of IL-
2 production and suppression by Tregs [262]. FOXP3 is also able to remodel chromatin and gene 
accessibility through binding of HAT/HDAC complexes via the repressor domain in the N-
terminus [263]. For example, Foxp3 gets acetylated by the HAT TIP60 which increases binding 
of Foxp3 to the Il2 promoter and increases repression of Il2 [264]. In Tregs with a Th phenotype, 
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FOXP3 is able to directly inhibit subset-specific transcription factors and reduce pro-
inflammatory activity [262, 265]. While the exact mechanism of FOXP3 activity have yet to be 
elucidated, it is clear that FOXP3 alters existing transcriptional machinery in a T cell to promote 
a Treg phenotype. 
 
Induction of FOXP3 in Tregs 
As described in the “Origin of Tregs” section above, multiple factors are critical for 
inducing FOXP3 expression in Tregs. These factors promote binding of transcription factors to 
one or more of the conserved non-coding sequences (CNSs) in the Foxp3 locus. Four FOXP3 
CNSs have been identified and each one is specific to different aspects of Treg function such as 
tTreg development, pTreg differentiation or maintenance of Treg stability [57]. The most critical 
factor in promoting FOXP3 expression in Tregs is IL-2 signaling via STAT5. A deficiency of IL-
2 or IL-2 signaling in both mice and humans leads to a significant decrease Treg numbers and 
increase in autoimmunity [262, 266-271]. STAT5 directly binds to CNS2 which maintains Treg 
phenotype and heritability of FOXP3 expression [272]. As previously described, TGFβ directly 
recruits Smad3 and NFAT to CNS1 [89, 108]. TGFβ also blocks demethylation of the TSDR in 
CNS2 which is required to maintain stable FOXP3 expression [109]. Binding of Treg TCR to 
cognate peptide on MHCII initiates FOXP3 expression in developing Tregs [273, 274].  TCR 
signaling activates multiple transcription factors involved in binding of Foxp3 CNSs such as 
NFAT, NFκB and AP-1 [68]. In addition to initiating FOXP3 expression, maintenance of a high 
level of FOXP3 has been demonstrated to be critical to retaining a Treg phenotype. Mice altered 
to have low levels of Foxp3 or induced loss of Foxp3 had a loss of Treg suppressive activity and 
an acquisition of effector T cell function [275, 276]. Thus, multiple factors not only initiate 
24 
 
FOXP3 in Tregs but must maintain FOXP3 expression in order for Tregs to maintain a 
suppressive phenotype. 
 
Role of FOXP3 in Treg function 
It is evident that FOXP3 is the key mediator of Treg function as knock out of FOXP3 in 
Tregs blocks suppressive activity and overexpression of FOXP3 in Tconv conveys expression of 
canonical Treg genes [193, 277]. All the effects of FOXP3 expression in Tregs are unknown but 
knock-down and knock-out studies have revealed a few functions. Specific downstream effects 
of FOXP3 activity have been previously described including inducing expression of Treg 
markers such as CD25 and CTLA-4 and repression of IL-2 [260, 278, 279]. FOXP3 directly 
binds to 20-30% of the genes it regulates and acts as both a transcriptional repressor or enhancer 
[280-282]. Interestingly, through RNA sequencing and microarray assay analysis, it has been 
demonstrated that FOXP3 overexpression in Tconvs is not enough to completely recapitulate a 
Treg transcriptional signature and part of the signature can be induced in the absence of FOXP3 
[283, 284]. Thus, while FOXP3 is the hallmark transcription factor in Tregs, other factors are 
required to completely convey a Treg phenotype.  
  
The Ikaros Family of Transcription Factors and Tregs 
In addition to FOXP3, members of the Ikaros family of transcription factors are highly 
expressed in Tregs [25, 46, 285]. The five members of the Ikaros family are Ikaros, Helios, 
Aiolos, Eos and Pegasus. Helios and Eos are highly expressed in a majority of Tregs [25, 285]. 
While the expression of Helios and Eos is well characterized, the downstream signaling and Treg 
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functions mediated by these transcription factors are less clear. This section will summarize what 
is known about all of the Ikaros family members in Treg development and function.  
 
Structure and downstream signaling 
Each Ikaros family member has four DNA-binding zinc finger motifs near the N-
terminus and two C-terminal zinc fingers that mediate protein-protein interactions [17].  Each 
family member can homodimerize or heterodimerize via the C-terminal zinc fingers in every 
possible combination [17-21].  Furthermore, each member can undergo alternative splicing that 
eliminates one or more of the N-terminal zinc fingers [22-24].  Deletion of more than two zinc 
fingers results in a dominant negative form of the protein that can dimerize with other family 
members but cannot bind DNA [17]. Thus, changes in one Ikaros family member often leads to 
changes in downstream signaling of all the family members. 
The two Ikaros family members that have been extensively studied in Tregs are Helios 
and Eos. Both Helios and Eos have been shown to be highly expressed in a majority of Tregs in 
both mice and humans [46, 285]. Moreover, ectopic expression of these transcription factors in 
mouse Tconvs has been demonstrated to convey part of the Treg signature [277] . Thus, these 
transcription factors play a major role in mediating the Treg phenotype. Downstream signaling of 
Helios and Eos in Tregs has yet to be fully elucidated but recent work in murine Tregs has shed 
light on the topic. Kim et al. [43] carried out ChIP-Seq analysis on Helios-bound sites in both 
CD4+ and CD8+ murine Tregs. These data revealed that Helios bound primarily promoter 
regions of genes involved in apoptosis and survival, cell cycle progression and autophagy. 
Importantly, the IL-2Rα-STAT5 pathway was a major target in the Helios gene network [43]. As 
previously described, the IL-2Rα-STAT5 pathway is crucial for maintaining Treg FOXP3 
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expression and survival [286]. While Helios does not directly interact with Foxp3, Eos is able to 
bind Foxp3 in murine Tregs and mediate downstream activity [285]. Eos interaction with Foxp3 
facilitates repression of pro-inflammatory genes such as Il2 or Ifng. Knocking down Eos in Tregs 
reduced Foxp3-mediated suppression of IL-2 production in murine Tregs [285].  Additionally, 
Eos recruits a co-repressor, C terminal binding protein 1 (CtBP1), to promoters and together, Eos 
and CtBP1 mediate histone modifications and methylation of genes that are silenced in Tregs 
[285]. Thus, while Helios primarily maintains high FOXP3 expression and improved survival in 
murine Tregs through STAT5 signaling, Eos aids in the gene silencing activity of FOXP3 and 
directly silences genes through mediation of epigenetic modifications.  
 
Expression of Ikaros family members during Treg development 
During our analysis of human T cell development, we tracked the expression patterns of 
Ikaros family members.  Using intracellular staining and flow cytometry, we showed that protein 
levels of Ikaros, Aiolos, and Helios increase when thymocytes undergo  selection, but the 
increase in Helios expression is greater than Ikaros and Aiolos.  Further, the increase observed 
for Ikaros and Helios was transient while Aiolos levels remained elevated as thymocytes 
continued to mature.  Similarly, the protein levels of Ikaros, Helios, and Aiolos increased when 
thymocytes underwent positive selection.  Again, the spike in Ikaros and Helios expression was 
transient while Aiolos levels remained elevated in subsequent thymocyte populations[77]. 
These data indicate that the ratio of Ikaros family members changes at  selection and 
positive selection, suggesting that the nature of the dimers likely changes.  The significance of 
changing the dimer composition as cells progress through T cell development is unknown, but it 
is likely to influence the transcriptional activity of the complex [287]. 
27 
 
Role of Ikaros family members in Treg function 
Most Tregs express Helios, including all thymic CD4+ Tregs and approximately 70% of 
circulating Tregs [25], and Tregs that lack Helios express Aiolos [46].  In both mice and humans, 
Helios+ Tregs more effectively suppress cytokine production by Tconv cells [45, 48], while 
Helios- Tregs secrete more pro-inflammatory cytokines, including IFN, IL-2, and IL-17 [46].  
Besides differences in functionality between Helios+ and Helios- Tregs, Helios+ Tregs are more 
stable under inflammatory conditions than Helios- Tregs [25, 47, 288, 289].  Knock-down of 
Helios in murine Tregs decreased immunosuppressive function and survival in vitro and 
increased pathology in a murine colitis model [290].  Conversely, overexpression of Helios in 
murine Tregs improved secretion of immunosuppressive cytokines and suppression of T cell 
proliferation in vitro [291]. Experiments with Treg-specific Helios knockout mice have further 
elucidated Helios’ role in Treg function in vivo. These mice developed spontaneous autoimmune 
disease at 6-8 months of age, which was attributed to increased numbers of activated CD4+ and 
CD8+ T cells and germinal center B cells [43]. Of the CD4+ T cells, T follicular helper (Tfh) 
cells and Type I helper T (Th1) cells were the most affected [42, 43]. Both CD4+ and CD8+ 
Tregs isolated from these mice demonstrated reduced suppression in an in vitro suppression 
assay in Rag2-/- mice [43]. Additionally, both these Treg subsets demonstrated increased 
apoptosis and reduced survival in vivo under inflammatory conditions [42, 43]. CD4+ Helios 
deficient Tregs also had increased IFNγ production when stimulated in vitro. Thus, Helios plays 
a major role in suppressing a pro-inflammatory phenotype in Tregs and promoting Treg survival. 
While it is clear that Helios expression maintains a suppressive phenotype in human Tregs, 
ectopic of Helios in Jurkat cells, a human T cell line, actually reduces survival [44]. Thus, there 
may be differences between the role of Helios in murine versus human Tregs.  
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Eos is also expressed in Tregs and is often co-expressed with Helios [46].  As previously 
described, Eos directly binds FOXP3 and is necessary for FOXP3-mediated gene repression 
[285, 292].  Eos can also inhibit expression of non-Treg genes such as IL-2 [277, 285, 288]. 
Tregs can convert into Tconv cells under inflammatory conditions and this process requires 
downregulation of Eos [288]. Additionally, knock-down of Eos via siRNA in Tregs results in 
reduced immunosuppressive activity both in vitro and in vivo in a murine colitis model [285]. 
Interestingly, Tregs isolated from Eos knock out mice did not differ from wild-type Tregs in 
immunosuppressive activity or cytokine secretion, indicating a redundant role for Eos in Tregs 
[293]. These differences in results were attributed to the possibility the siRNA knock down of 
Eos may allow for expression of dominant-negative isoforms of Eos resulting in differing 
downstream effects compared to the global mouse knock out. Thus, the Ikaros family members 
can control the stability and phenotype of Tregs and mediate very specific functions in Tregs.  
 
Treg therapy and engineered Tregs 
The immunosuppressive properties of Tregs have led to much research into utilization of 
Tregs as therapy for a variety of inflammatory diseases.  In general, Tregs are isolated from 
patients or a third party, non-immunogenic source, such as umbilical cord blood (UCB), 
expanded ex vivo and transfused back into patients. Trials for multiple diseases such as GVHD, 
IBD and Type I diabetes have shown that Treg infusions are safe, but only moderately successful 
[35-39]. A major challenge is expanding Tregs to numbers required to treat disease. Another 
difficulty of Treg therapy is isolating a pure population of Tregs. Tregs are commonly isolated 
by selecting CD4+ and CD25+ T cells but these markers are also expressed by activated Tconvs 
[22]. This leads to potential contamination of Tregs with Tconvs that could exacerbate disease. 
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Another limitation of Treg therapy is stability of phenotype as Tregs can convert to a Tconvs and 
lose immunosuppressive activity [198].  
Given these challenges in utilizing expanded Tregs from blood for treatment of 
inflammatory disease, alternative approaches have been investigated. Because Tregs represent 
rare populations in vivo, attempts have been made to produce them in culture [23]. For example, 
in vitro-induced Tregs (iTregs) can be generated by stimulating CD4+ T cells with various 
cytokines and drugs such as TGF, rapamycin and retinoic acid [31]. However, current iTregs do 
not retain FOXP3 expression and do not effectively treat a humanized model of GVHD [31]. 
tTregs from discarded human thymus have also been explored as a source of Tregs for therapy. 
Larger numbers of Tregs could be isolated from the thymus and they remained stable under 
inflammatory conditions, unlike Tregs from peripheral blood. Furthermore, expanded tTregs 
delayed GVHD in a xenogeneic murine GVHD model more effectively than Tregs from 
peripheral blood [289]. These data indicate that Treg therapy has great potential, but there is 
much room for improvement. 
Another approach to overcome the limitations of Treg therapy is the generation of 
engineered Tregs (eTregs). eTregs are created by expressing known Treg genes via retroviral or 
lentiviral transduction of CD4+ T cells isolated from peripheral blood. Total CD4+ T cells make 
up about 4-20% of total leukocytes and can be isolated in greater numbers and expanded more 
quickly than naturally occurring Tregs. Co-expression of Treg genes with a transduction marker 
allows for purification of transduced cells and ensures homogeneity [294]. Additionally, an 
inducible caspase can be included in the DNA construct that can act as a suicide gene should the 
engineered Tregs result in any unwanted side effects [295]. Constitutively expressing Treg 
transcription factors should stabilize the Treg phenotype by out-competing any other 
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transcription factors that could convert the Treg into a Tconv. Finally, engineered Tregs can be 
designed to express receptors that can target them to a specific tissue, resulting in localized 
immunosuppression. While the advantages of engineered Tregs are clear, the Treg genes 
necessary to create an optimal engineered Treg are still undefined.  
As previously described, enforced FOXP3 expression in Tconvs is able to convey 
immunosuppressive function in both human and murine T cells [14, 32]. These FOXP3 
expressing eTregs were able to reduce proliferation of responder cells and delay disease in 
murine colitis and GVHD models [14, 32, 255]. However, when compared to endogenous Tregs 
in a murine arthritis model, FOXP3 eTregs were not as effective at reducing symptoms [296]. 
This is expected as Hill et al. [277] demonstrated that ectopic Foxp3 expression in murine Tconv 
only partially conveys a Treg gene signature. Another characteristic of Tregs is the secretion of 
the immunosuppressive cytokine IL-10 [165]. Ectopic expression of IL-10 in Tconvs ameliorated 
disease in murine IBD models but not as efficiently as naturally occurring Tregs [297]. Other 
Treg mechanisms that could be incorporated into eTregs are killing of immune cells via perforin 
or granzyme B and contact-dependent regulation of immune cells via molecules such as CTLA-4 
or LAG-3 [33].  
My dissertation work addressed whether Helios expression improves the function of 
FOXP3-transduced eTregs. In addition to FOXP3, the Ikaros transcription factor Helios is highly 
expressed in about 70% of FOXP3+ Tregs [25]. tTregs have been demonstrated to suppress more 
effectively than pTregs and tTregs express higher levels of Helios than pTregs [11, 21].  Helios+ 
Tregs can more effectively suppress Tconv cytokine secretion and are more stable under 
inflammatory conditions than Helios- Tregs [9, 20, 21].  Knock-down of Helios in Tregs 
decreased immunosuppressive function in vitro and in vivo in a murine IBD model [23]. 
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Furthermore, enforced Helios expression in Tregs has been demonstrated to improve Treg 
function [24]. Finally, ectopic expression of both Helios and Foxp3 in murine CD4+ Tconvs 
increased the Treg signature index compared to Tconvs expressing Foxp3 alone [298]. Thus, the 
hypothesis of my thesis was that ectopic expression of Helios with FOXP3 in eTregs would 
result in improved immunosuppression and stability of FOXP3 transduced eTregs. 
 
Graft versus Host Disease (GVHD) 
GVHD is the most common disease being studied in the Treg therapy field and the work 
in this dissertation used a xenogeneic graft versus host disease model. Allogeneic hematopoietic 
stem cell transplants (HSCT) have become routine treatment for patients suffering from 
hematological malignancies such as leukemia [299]. A significant complication of HSCT is 
graft-versus-host disease (GVHD), which affects approximately 50% of HSCT patients and is 
lethal in approximately half of the patients who suffer from GVHD [300]. GVHD occurs when 
donor-derived T cells present in the graft attack recipient’s organs. Acute GVHD (aGVHD) and 
chronic GVHD (cGVHD) are defined by different clinical symptoms caused by an underlying 
difference in immunopathology and timing of disease onset [301]. aGVHD presents as rapid 
systemic inflammation and multi-organ dysfunction driven primarily by activated T cells while 
cGVHD presents as a late-onset autoimmune-like disease mediated by both T cells and B cells 
[301]. This section will focus on the pathogenesis and pre-clinical studies of aGVHD. The only 
successful therapy includes highly immunosuppressive drugs, which increase the risk of 
infection and are highly toxic [302, 303]. Because these drugs are unsuccessful in half of GVHD 
patients [304],  there is a critical need for improved GVHD therapies with minimal toxicity that 





 It is difficult to fully match major and minor antigens for bone marrow donors and 
recipients. Thus, many HSCT patients receive grafts from partially matched donors and 
alloreactivity is kept under control with immunosuppressants. This immunosuppression is 
ineffective in 30-50% of patients who develop GVHD. Acute GVHD develops when donor 
immune cells are transferred along with donor stem cells. The presence of donor immune cells is 
required for proper engraftment of stem cells, prevention of infection and a graft-versus-tumor 
effect to help clear cancerous cells [305-307]. In GVHD, donor T cells are activated by APCs 
presenting host antigens following tissue damage caused by the conditioning regimen. The 
activated T cells then secrete inflammatory mediators that recruit and activate other arms of the 
immune system which results in a systemic inflammatory response [308]. Symptoms of disease 
include multi-organ failure, predominantly in the gut and the liver, and skin pathologies [309].  
 
Murine models of GVHD 
Acute GVHD models have been developed in mice, canines, pigs, and non-human 
primates. The most common models are the major histocompatibility complex (MHC)-mismatch 
mouse model and the xenogeneic mouse model (xenoGVHD) [1, 301]. Both models are lethal, 
and acute GVHD progression is tracked over time using a clinical scoring system described by 
Cooke and colleagues [310]. Briefly, five clinical signs are assessed on a scale of 0, 1, or 2 at 
several time points: weight loss, posture, fur texture, skin integrity and activity. Most studies aim 
to cure GVHD in these models but often a delay in disease progression is observed rather than 
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total prevention of disease due to the robust immune response to mismatched allografts and 
xenografts.  
In the MHC-mismatch model, lethally irradiated mice receive splenic T cells and T cell-
depleted bone marrow cells from MHC-mismatched mice. The mice engraft with donor 
hematopoietic cells and transplanted CD4+ and CD8+ T cells target allogeneic tissue antigens 
leading to the disease manifestations.  Mice will develop acute GVHD by 10-20 days. C57BL/6 
(H-2b)→ BALB/c (H-2d) is the most commonly used MHC-mismatch model [311].  The other 
major acute GVHD murine model is the xenoGVHD model, which involves sublethal irradiation 
of NOD-SCID IL-2Rγnull (NSG) mice followed by IV injection of human peripheral blood 
mononuclear cells (PBMCs), causing death from acute GVHD in 30-50 days [312, 313]. In this 
model, human T cells, primarily CD4+ T cells, are activated by human antigen presenting cells 
(APCs) among the PBMCs [314].  These T cells then expand and traffic to target organs such as 
the lung, liver, kidney and skin [315, 316]. 
As with all murine models, there are limitations with the xenoGVHD and MHC-
mismatch models [317]. The radiation dose, mouse strain, anatomical sites of T cell transfer, and 
microbial environment can all affect disease severity and lead to experimental variability. Other 
factors that differ from standard clinical practice include the use of irradiation as the only form of 
conditioning and the lack of GVHD prophylaxis in control groups [301, 318]. Large animal acute 
GVHD models in canines, pigs, and non-human primates may offer more human-like conditions 
to study acute GVHD but required specialized expertise [319-321]. Despite these limitations, 
insights from animal studies have led to what is now the standard of care for the treatment and 




Treg Therapy in GVHD  
Pre-clinical studies of Treg therapy for prevention of disease in murine models of GVHD 
has yielded promising results.  Multiple studies have demonstrated that murine Treg infusion is 
able to control GVHD in a murine MHC-mismatch model  [322-324]. Furthermore, Treg 
treatment did not prevent a graft-versus-tumor affect in murine tumor models [322-324]. 
Infusion of human Tregs in the xenoGVHD model were also able to prevent disease mediated by 
human T cells. These studies tested human Tregs from a variety of sources including peripheral 
blood, umbilical cord blood, discarded human thymus and in vitro induced Tregs [289, 325-329]. 
These studies have revealed mechanisms of Treg-mediated immunosuppression that are critical 
for delaying disease in the xenoGVHD model. Hahn et al. [330] demonstrated that 
administration of soluble Glycoprotein A repetitions predominant (GARP) improved human 
Treg prevention of xenoGVHD. Conversely, blocking GARP/TGFβ1 interaction with 
monoclonal antibodies was able to inhibit Treg-mediated immunosuppression in xenoGVHD 
mice [331] . Additionally, Bacher et al. [332] found that IFNα was able to reverse the protective 
effect of Tregs in xenoGVHD by suppressing cAMP in Tregs. Arginine methylation of FOXP3 
in Tregs was also found to be critical in maintaining suppressive function of Tregs in 
xenoGVHD (Kagoya et al. 2018). Thus, both murine and human Treg infusions are able to 
prevent disease in two murine GVHD models and these pre-clinical studies provide insight into 
the mechanisms necessary for Treg-mediated suppression of GVHD. 
There are currently ten phase I or II clinical trials in the recruiting or ongoing utilizing 
Tregs in GVHD prevention or treatment. Five phase I clinical trials studying Treg treatment or 
prevention of GVHD have been completed and results published. These studies have 
demonstrated that Treg infusions derived from autologous T cells, allogeneic T cells or UCB are 
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safe and non-toxic. The first in-human trial with adoptive Treg transfer as a treatment for acute 
and chronic GVHD (aGVHD and cGVHD) was carried out by Trzonkowski et al. in 2009 [333]. 
Unfortunately, due to limited patient numbers and complications in Treg production, nothing 
could be concluded about safety. Brunstein et al. [37] carried out the first clinical trial with UCB-
derived Tregs and treated 23 patients with aGVHD. This treatment resulted in a decrease in 
grade II-IV aGVHD incidence compared to historical controls.  However, there was an issue 
with expanding enough Tregs for treatment, and six out of 13 Treg products did not reach the 
target cell levels [37]. Martelli et al. [334] also had promising results after infusing 43 patients 
with high risk leukemia with freshly isolated donor-derived Tregs. This was the first study that 
examined Treg therapy in patients that also received donor Tconv in addition to a HSCT. There 
was a complete absence of GVHD in patients who received 2x106 Tregs along with improved 
reconstitution of the immune system and reduced leukemia relapse. Theil et al. [335] tested Treg 
therapy in five patients with cGVHD. They combined Treg infusion with low dose IL-2 to 
improved Treg survival which was well tolerated by the patients. Moreover, all the patients 
experienced improved disease symptoms or at least stability of symptoms. The low dose IL-2 did 
increase T cell activation but did not negatively affect the benefits of the Treg infusion. Finally, 
the ALT-TEN trial carried out by Bacchetta et al. [336] used Tr1 cells rather than FOPX3+ 
CD4+Tregs to treat patients who underwent chemotherapy and T cell-depleted HSCT due to a 
high risk/advanced hematological malignancy. Unfortunately, few conclusions could be drawn 
from this study as only four patients survived and the purity of the Tr1 cell product was low. In 
conclusion, it is clear there is potential for Treg therapy as a treatment for GVHD but there are 
many obstacles, including improving Treg cell number and purity, that still need to be overcome.  
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Chapter 2 : Ectopic expression of the two major isoforms of Helios with FOXP3 play 
different roles in mediating engineered regulatory T cell immunosuppression 
Abstract  
Regulatory T cells (Tregs) are a subset of immune cells that suppress the immune 
response. Treg therapy for inflammatory diseases is being tested in the clinic with moderate 
success. However, it is difficult to isolate and expand Tregs to sufficient numbers. Engineered 
Tregs (eTregs) can be generated in larger quantities by genetically manipulating conventional T 
cells to express FOXP3. These eTregs can suppress in vitro and in vivo but not as effectively as 
endogenous Tregs. We hypothesized that ectopic expression of the transcription factor Helios 
along with FOXP3 is required for optimal eTreg immunosuppression. To test this, we generated 
eTregs by retrovirally transducing total human T cells with combinations of FOXP3, Helios 
(Hel-FL) and Δ3B Helios (Hel-Δ3B), a relevant splice variant of Helios. FOXP3+Hel-FL eTregs 
were the only eTregs able to delay disease in a xenogenic Graft versus Host Disease model. In 
vitro, FOXP3+Hel-FL CD4+ eTregs suppressed T cell proliferation more effectively than 
FOXP3 and FOXP3+Hel-Δ3B CD4+ eTregs. However, both FOXP3+Hel-FL CD8+ eTregs and 
FOXP3+Hel-Δ3B CD8+ eTregs were more effective than FOXP3 alone. RNA Sequencing of the 
CD4+ and CD8+ eTregs demonstrated that the addition of Hel-FL to FOXP3 in eTregs changed 
gene expression in cellular pathways and the Treg signature compared to FOXP3 alone or 
FOXP3+Hel-Δ3B. Thus, overexpression of Hel-FL with FOXP3 in eTregs changed gene 
expression in Tconvs and mediated immunosuppression in vivo and in vivo. Additionally, there is 
a functional difference between the endogenous splice variants of Helios in mediating CD4+ and 





Tregs are a subset of T cells that promote immune tolerance and suppress the immune 
response. Tregs represent 3-5% of CD4+ T cells in the blood and are characterized by the 
expression of the FOXP3 transcription factor, high CD25 and low CD127 expression. A majority 
of Tregs are thymus-derived Tregs (tTregs), generated in the thymus during T cell development. 
Naïve T cells can also differentiate into peripherally-derived Tregs (pTregs). Tregs mediate 
immune homeostasis through suppression of immune activity [33]. Tregs down-regulate the 
immune response via a variety of mechanisms such as inhibiting pro-inflammatory conventional 
T cells (Tconv) proliferation and activation, secretion of immunosuppressive cytokine, killing of 
reactive immune cells and induction of anergy. 
The immunosuppressive properties of Tregs have led to much research into utilization of 
Tregs as a cellular therapeutic.  The most numerous clinical trials are aimed at preventing Graft 
versus Host Disease (GVHD) in which Tregs are isolated from leukopheresed blood and co-
infused with hematopoietic stem cells [337].  Alternatively, Tregs can be expanded from cord 
blood [329]. Other clinical trials are testing Tregs as treatment for inflammatory bowel disease, 
type I diabetes and transplant rejection [35-39]. These trials have shown that Treg infusions are 
safe, but only moderately successful. A major challenge is expanding Tregs to numbers required 
to treat. For example, in GVHD one trial, six out of 13 Treg products did not reach the target cell 
levels [37]. Another major challenge of Treg therapy is isolating a pure population of Tregs. 
Tregs are commonly isolated by selecting CD4+ CD25+ T cells, but these markers are also 
expressed by activated Tconvs [22]. This leads to potential contamination of Tregs with Tconvs 
that could exacerbate disease. Another limitation of Treg therapy is stability of phenotype as 
Tregs can convert to a Tconvs and lose immunosuppressive activity[198].  
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Given these challenges in utilizing expanded Tregs from blood, alternative approaches 
are being investigated. Because Tregs represent rare populations in vitro, attempts have been 
made to produce them in culture [23]. For example, in vitro-induced Tregs (iTregs) can be 
generated by stimulating CD4+ T cells with various cytokines and drugs such as TGF, 
rapamycin and retinoic acid [31]. However, the iTregs that have been generated up until now do 
not retain FOXP3 expression and do not effectively treat a humanized model of GVHD [31]. 
tTregs from discarded human thymus have also been explored as a source of Tregs for therapy. 
Larger numbers of Tregs can be isolated from the thymus and they remain stable under 
inflammatory conditions, unlike Tregs from peripheral blood. Furthermore, expanded tTregs 
delayed GVHD in a xenogeneic murine GVHD model more effectively than Tregs from 
peripheral blood [289]. These data indicate that Treg therapy has great potential, but there is 
much room for improvement. 
Engineered Tregs (eTregs) are generated by transducing CD4+ Tconvs with genes known 
to convey Treg activity such as FOXP3. The same T cell transduction technology is currently 
being used to express chimeric antigen receptors in T cells for cancer immunotherapy and has 
been proven to be safe [338]. eTregs provide solutions to many of the limitations of endogenous 
Tregs. Total CD4+ T cells can be isolated in greater numbers and expanded more quickly than 
naturally occurring Tregs. Co-expression of Treg genes with a transduction marker allows for 
purification of transduced cells and ensures homogeneity of the cell population [294]. 
Constitutively expressing Treg transcription factors stabilizes Treg phenotype [296]. Finally, 
eTregs can be modified to express receptors, such as chimeric antigen receptors, that can target 
them to a specific tissue resulting in localized immunosuppression [296]. While the advantages 
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of eTregs are clear, the Treg genes necessary to create an optimal engineered Treg are still 
undefined.  
High expression of the transcription factor FOXP3 is a hallmark of naturally occurring 
Tregs. FOXP3 is necessary for Treg-mediated immune homeostasis, as mice and humans 
deficient in FOXP3 develop severe autoimmune diseases [17, 18]. Enforced FOXP3 expression 
in human CD4+ T cells mediates suppression of Tconv proliferation in vitro [32]. FOXP3-
transduced cells can reduce symptoms in murine colitis and GVHD models [14, 255]. However, 
in a study using a murine arthritis model, FOXP3-transduced cells were not as effective as 
endogenous Tregs at reducing joint destruction or decreasing the number of pathogenic Th17 
cells in the joint [296]. Additionally, microarray data has shown that FOXP3 is not sufficient to 
convey complete Treg gene regulation in murine T cells [277]. These observations indicate that 
FOXP3-expressing eTregs show promise, but expression of additional genes are required to 
completely mimic endogenous Treg function. 
In addition to FOXP3, the transcription factor Helios, a member of the Ikaros family, is 
highly expressed in about 70% of FOXP3+ Tregs [25]. Treg-specific knock out mice develop 
spontaneous autoimmune disease at 6-8 months of age and Tregs from these mice have reduced 
suppressive activity and survival [42, 43]. In humans, FOXP3+ Helios+ Tregs more effectively 
suppress Tconv cytokine secretion and are more stable under inflammatory conditions than 
FOXP3+ Helios- Tregs [25, 288, 289]. It has been demonstrated that co-expression of Helios and 
Foxp3 in murine CD4+ Tconvs increases Treg transcriptional signature index compared to 
Foxp3 alone [298]. For these reasons, we hypothesized that ectopic expression of the Helios with 
FOXP3 is required for optimal eTreg immunosuppression. Here, we report that through dual 
retroviral transduction, total human T cells can be genetically modified to express high levels of 
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FOXP3 and Helios. We generated eTregs that co-expressed FOXP3 with the following two 
endogenous splice variants of Helios found in human Tregs [40, 41]: full length Helios (Hel-FL) 
and a shorter form, Δ3B Helios (Hel-Δ3B). FOXP3+Hel-FL eTregs were the most effective at 
immunosuppression in vivo in a xenogeneic GVHD model and in an in vitro suppression assay. 
Adding Hel-FL to FOXP3 in eTregs was able to convey immunosuppressive properties to both 
CD4+ and CD8+ human Tregs and these eTregs had differential gene expression and enrichment 
of cellular pathways at a transcriptional level compared to FOXP3 and FOXP3+ Hel-Δ3B 
eTregs. Thus, we were able to improve current eTreg production and generate both CD4+ and 




Materials and Methods 
Isolation of Human Peripheral Blood Mononuclear Cells (PBMC)  
All studies involving human subjects were conducted in accordance with the guidelines 
of the World Medical Association's Declaration of Helsinki. Blood was collected from healthy 
adult volunteer donors under signed informed consent with approval from the Institutional 
Review Board of the University of Kansas Medical Center. Blood was collected in heparin tubes 
and PBMC were isolated via Ficoll-Paque (GE Healthcare, Chicago, IL) density centrifugation 
with SepMate tubes (STEMCELL Technologies Inc., Vancouver, BC).  
 
Construction and production of retroviral vectors 
Retroviral constructs were generated to express cDNA for FOXP3, full length Helios 
(Hel-FL) or a short isoform of Helios (Hel-Δ3B). The NCBI Reference Sequences for FOXP3, 
Hel-FL and Hel-Δ3B are NM_014009.3, NM_016260.2 and NM_001079526.1, respectively. 
The SFG retroviral vector, RDF and pEQPAM3 retroviral packaging plasmids were generously 
donated by Dr. Malcom Brenner at Baylor College of Medicine. Genes were cloned into the SFG 
vector via Gibson Assembly [339]. The expression of cDNA is driven by a strong retroviral 
promoter in the 5’ LTR. Multiple genes of interest were expressed by linking them in frame with 
a picornavirus 2A ribosomal skip peptide, which ensures equivalent expression of multiple 
proteins [292]. The FOXP3 construct contains truncated CD19 (ΔCD19) cDNA and the Hel-FL 
and Hel- Δ3B contains truncated CD34 (ΔCD34) cDNA which act as transduction markers and 
allowed for purification of transduced cells via antibody-bound magnetic beads. The NCBI 
Reference Sequences for CD19 and CD34 are NM_001178098.1 and NM_001025109.1 
respectively. The truncated ΔCD19 and ΔCD34 sequences only contain the signal peptide, 
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extracellular and transmembrane regions of the protein. ΔCD19 and ΔCD34 alone vectors were 
generated as negative controls. FOXP3, ΔCD19 and ΔCD34 were codon optimized with the 
Invitrogen GeneArt Gene Synthesis service (Thermo Fisher Scientific, Waltham, MA) prior to 
being cloned into the SFG vector. Hel-FL and Hel-Δ3B gene sequences were not altered prior to 
cloning. Viral particles were generated by transfecting HEK 293T cells with SFG vectors 
containing the genes of interest and the retroviral packaging vectors. Transfection was carried 
out with Fugene HD Transfection Reagent (Promega, Madison, WI). Viral supernatants were 
collected 2 and 3 days after transfection and stored at -80 C until use.  
 
Activation and Transduction of Human T cells 
Human T cells were activated in complete media containing Aim V medium (Thermo 
Fisher Scientific, Waltham, MA) and 2% human AB serum (Bio-Techne, Minneapolis, MN). 3 x 
106 PBMCs at 106/mL were stimulated with plate bound anti-CD3 (2 µg/mL OKT3; Bio X Cell, 
West Lebanon, NH) and anti-CD28 (2 µg/mL 9.3; West Lebanon, NH). After 2 days of 
activation, complete medium was supplemented with 200 U/mL of recombinant human IL-2 
(rhIL-2) (PeproTech, Rocky Hill, NJ). Cells were passed every 2-3 days at 1-2 x 106 cells/ml in 
complete medium supplemented with rhIL-2 at 200 U/mL. Activated T cells were transduced 
with viral supernatants containing ΔCD34 vectors 5-6 days post activation. Non-tissue culture 6 
well plates were coated in Retronectin (Takara Bio Inc., Kusatsu, Shiga Prefecture, Japan) at 20 
µg/mL in PBS overnight at 4 °C or 2 hours at room temperature. 1.5 mL of viral supernatant per 
well was bound to Retronectin coated plates by centrifuging plates for 2 hours at 2000 xg at 32 
°C. Viral supernatant was removed and 1.5 mL of viral supernatant along with 2.5-3 x 106 T cells 
were added to each well. T cells were in complete medium with rhIL-2 at 200 U/mL at 106 
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cells/mL. Transduced cells are positively selected 2 days post transduction with anti-human 
CD34 CELLection magnetic beads (Thermo Fisher Scientific, Waltham, MA). Beads were 
removed with a magnet 2 days later and cells were transduced with viral supernatants containing 
ΔCD19 vectors as previously described. Transduced cells were positively collected 2-3 days post 
transduction with CELLection Biotin Binder Kit beads (Thermo Fisher Scientific, Waltham, 
MA) coated with biotinylated anti-human CD19 (HIB19, Biolegend, San Diego, CA). Beads 
were removed 2 days later and used in assays up to 10 days post the last transduction. The 
resulting cell strains were ΔCD19+ΔCD34, FOXP3-ΔCD19+ΔCD34, FOXP3-ΔCD19+ Hel-FL-
ΔCD34 and FOXP3-ΔCD19+ Hel-Δ3B-ΔCD34.  
 
Real time PCR  
Helios splice variants were detected in transduced cell strains using real time PCR. RNA 
was isolated from cells using the Qiagen RNeasy Mini Kit (Qiagen, Germany). RNA was 
converted to cDNA using the Taqman High Capacity RNA to cDNA kit (Thermo Fisher 
Scientific, Waltham, MA). Real time PCR was performed using the following primers for 
Helios: F 5’ TGATGGCTATATAACGTGTGACAA 3’, R 5’ 
CTCACACTTGAAGGCCCTAATC 3’. Splice variants were visualized using gel 
electrophoresis.  
 
Mice and Xenogeneic Murine GVHD Model  
All animal studies were performed in compliance with the U.S. Department of Health and 
Human Services Guide for the Care and Use of Laboratory Animals. NOD-SCID IL-2Rγnull 
(NSG) mice were purchased from Jackson Laboratories and bred at the University of Kansas 
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Medical Center.  Mice were maintained under specific pathogen-free conditions using sterile 
food, water, bedding, and caging.  
NSG mice (8-12 weeks old) of both sexes received 1.5 Gy of whole body irradiation. The 
next day, the mice were anesthetized via 2% inhaled isoflurane and injected retro-orbitally with 
107 human PBMC alone, 107 PBMCs with 5 X 106 eTregs or PBS alone. Cells were re-
suspended in 100 l of sterile PBS. Mice were examined for signs of GVHD, using the GVHD 
scoring system established by Cooke et al. [310]. Five categories were assessed on a scale of 0, 
1, or 2 for each. Weight loss: 0= <10% change, 1= 10-25% change, 2= >25% change, Posture: 
0= normal, 1= hunching at rest, 2=hunching impairs movement, Fur texture: 0= normal, 1= mild 
to moderate ruffling, 2= severe ruffling, Skin integrity: 0=normal, 1=scaling of paws/tail, 2= 
obvious areas of denuded skin, Activity: 0=normal, 1=mild to moderately decreased, 
2=stationary unless stimulated. Mice were sacrificed when they reached a GVHD score of ≥7 or 
lived until 42 days. The researcher assessing score was blinded to the treatment of each mouse. 
Serum was collected to be analyzed for cytokines, the spleen was collected for flow cytometry 
and samples from the ear, lung, liver and kidney were frozen for digital PCR. 
 
Flow Cytometry 
Culture cells or single cell suspensions of spleens from mice were stained with various 
combinations of the following anti-human antibodies: CD3 APC-Cy7, CD4 PE-Cy7, CD4 
eFluor-610, CD8 Alexa Fluor 488, CD8 Brilliant Violet 785, CD19 Brilliant Violet 421, CD34 
Brilliant Violet 605, CD39 Brilliant Violet 510, CD25 PerCPCy-5.5, CD127 Brilliant Violet 650, 
CD73 APC-Cy7, CCR4 PE-Cy7, GITR PE-Cy5, CTLA-4 PE, CD62L AF700 (BioLegend, San 
Diego, CA). Intracellular transcription factor staining was done using the eBioscience™ FOXP3 
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Staining Buffer kit (Thermo Fisher Scientific, Waltham, MA) with anti-human FOXP3 PE, anti-
human Helios Alexa Fluor 647, anti-Helios Brilliant Violet 421(BioLegend, San Diego, CA). 
Samples were run on a Becton-Dickson LSRII (Becton-Dickson, Franklin Lakes, NJ) or Attune 
NxT (Thermo Fisher Scientific, Waltham, MA).  
 
Cytometric Bead Array 
Serum samples from mice were analyzed for cytokines using the 13-plex CD8/NK 
Legendplex Kit (Biolegend, San Diego, CA).  
 
Digital PCR 
Genomic DNA was isolated from mouse tissue samples with a Qiagen DNeasy Kit. 
Digital PCR reactions were prepared according to the protocol for EVA Green binding dyes for 
the BioRad LX200 digital PCR machine (Biorad, Hercules, CA). 0.5 μL of the restriction 
enzyme HindIII was added to each reaction to digest the genomic DNA. The following primers 
were used to detect human CD3 epsilon genomic DNA (NCBI Reference Sequence: 
NG_007383.1): Forward Primer: 5’ AGGCTGCCTTAACTCCCAAG 3’, Reverse Primer: 5’ 
GCCCTACCAGCTGTGGAAAC 3’. The following primers were used to detect the codon 
optimized CD19 present in the transduced eTregs: Forward Primer: 5’ 
CTTCAACGTGTCCCAGCAGA 3’, Reverse Primer: 5’ GATCCTTCCACGTTCACGGT 3’. 
Both these primers will yield a single band of 105 bp. Digital PCR reaction conditions were as 
follows: Lid at 105 °C, 95 °C for 10 min (1 cycle); 95 °C for 30 s, ramp 2 °C/s and 55 °C for 1 




Activation Induced Cell Death Assay 
Cells were resuspended at a concentration of 106 cells/mL in complete Aim V media. 
2x105 cells from each cell strain were stimulated with plate-bound anti-CD3 (10 µg/mL OKT3; 
Bio X Cell, West Lebanon, NH) and anti-CD28 (1 µg/mL 9.3; West Lebanon, NH) for 2, 4 or 6 
days. Cells were collected at each time point and stained with Zombie Green Fixable Viability 
Dye and Annexin V PE (Biolegend, San Diego, CA) and assessed for cell death via flow 
cytometry.  
 
Intracellular Cytokine Staining  
Cells were resuspended at a concentration of 106 cells/mL in complete Aim V media. 
2x105 cells from each cell strain were stimulated with plate-bound anti-CD3 (10 µg/mL OKT3; 
Bio X Cell, West Lebanon, NH) and anti-CD28 (1 µg/mL 9.3; West Lebanon, NH) for 6 hours in 
the presence of Golgi Stop (Becton-Dickson, Franklin Lakes, NJ) and Brefeldin A (Sigma 
Aldrich, St. Louis, MO). Cells were stained with the following extracellular antibodies: anti-
human CD4 PE-eFluor610 (Becton-Dickson, Franklin Lakes, NJ), anti-human CD8 Brilliant 
Violet 785 and anti-human CD19 APC-Cy7 (Biolegend, San Diego, CA). Afterwards, cells were 
fixed with 2% paraformaldehyde (Sigma Aldrich, St. Louis, MO) and permeabilized with 
permeabilization buffer from the eBioscience™ FOXP3 Staining Buffer kit (Thermo Fisher 
Scientific, Waltham, MA) and stained with the following antibodies: anti-human IL-2 FITC, 
anti-human IFNγ Pacific Blue, anti-human IL-10 Alexa Fluor 647 or anti-human IL-21 Alexa 
Fluor 647, anti-human IL-4 PE-Cyanine-7, anti-human IL-17A Brilliant Violet 605 (Biolegend, 





Autologous target T cells were labeled with the eBioscience™ Cell Proliferation Dye 
eFluor670 from (Thermo Fisher Scientific, Waltham, MA) and co-cultured with each eTreg cell 
strain at a 1:1 ratio with no stimulation or stimulation with anti-CD3 and anti-CD28 coated 
DYNAL™ Dynabeads™, Human T-Activator (Thermo Fisher Scientific, Waltham, MA) at 1:10 
bead: target cell ratio. The final concentration of cells was at 5x105 cells/ml. After 96 hours, 
target cell proliferation was assayed via flow cytometry. Cells were also stained with Zombie 
Green Fixable Viability Die and anti-human CD4 PE-Cy7, anti-human CD8 PE, anti-human 
CD19 APC-Cy7, anti-human CD25 PerCPCy5.5 (Biolegend, San Diego, CA). 
 
RNA Sequencing 
FOXP3-ΔCD19+ΔCD34, FOXP3-ΔCD19+ Hel-FL-ΔCD34 and FOXP3-ΔCD19+ Hel-
Δ3B-ΔCD34 cells were generated from PBMCs isolated from three different healthy human 
donors. Cells were collected Day 5 after the second transduction and stained with anti-human 
CD4 Pacific Blue and anti-CD8 Alexa Fluor 488 (Biolegend, San Diego). CD4+ and CD8+ cells 
were isolated via flow cytometry assisted cell sorting on a BD FACS Aria III. RNA was isolated 
using a Qiagen RNeasy Mini Kit (Qiagen, Germany). TruSeq stranded mRNA sequencing 
libraries were performed using the Illumina TruSeq Sample preparation kits and NuGEN sample 
preparation kit and paired end RNA sequencing data was generated using an Illumina NovaSeq 
6000 Sequencing System (Illumina, San Diego, CA).  
Adaptor removal was performed by cutadapt [340]. After adaptor removal, QC was done 
with fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Samples were then 
aligned to human genome (hg38) with RSEM [341] and bowtie2 [342], after which transcript 
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counts were obtained. Using the Bioconductor package “edgeR” [343], we first normalized the 
data by library size and then filtered out genes that have low expression. Genes were retained if 
their cpm (count per million) value was larger than 1 for at least two samples out of the 18 total 
considered in this study. After filtering low/non-expressed, 13,955 remained for subsequent 
statistical analysis (S1).  Next, we performed a series of differential expression analyses, 
comparing gene expression between different pairs of cell types. There were a total of six 
comparisons being performed: FOXP3 CD4 vs FOXP3 Helios-FL CD4, FOXP3 CD4 vs FOXP3 
Helios-d3B CD4, FOXP3 CD8 vs FOXP3 Helios-FL CD8, FOXP3 CD8 vs FOXP3 Helios-d3B 
CD8, FOXP3 Helios-FL CD4 vs FOXP3 Helios-d3B CD4, FOXP3 Helios-FL CD8 vs FOXP3 
Helios-d3B CD8. For each comparison, a volcano plot depicting the -log(p-value) as a function 
of log-fold change in expression, was generated. 
We further filtered genes with differential expression by taking 2,000 genes with the 
lowest false discovery rate (FDR) (S2). We then restricted this gene list to genes with an 
expression change that was the same direction in all 3 donors. We made these filtered lists for 
each donor and comparison and used the CPMs to carry out gene set enrichment analysis 
(GSEA) with the GSEA v3.0 software from the Broad Institute. We looked at enrichment in the 
KEGG pathway gene sets (c2.cp.kegg.v6.2.symbols.gmt) to identify and visualized significantly 
enriched pathways in different eTreg cell strain comparisons [344, 345].  
In order to examine the Treg related gene expression, we generated heatmaps based the 
cpm value from count data. More specifically, we compiled two lists of Treg genes based on 
comparisons of Tconvs vs Tregs generated by Miyara et al., Mold et al. and Bonacci et al. [133, 
346, 347], referred to as the “up gene list “ and the “down gene list”. On the basis of the 
differential expression results generated for gene expression comparisons of specific cell types, 
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we first subset the genes that had a nominal, uncorrected p value < 0.05 based on either up or 
down Treg gene list. Then, we filtered genes that only show expected expression pattern, aka, all 
three subjects are up regulated in an up_gene comparison or vice versa, so that we kept up 
regulated genes in an up_gene heatmaps and kept down regulated genes in down_gene heatmaps. 
Further, we merged two comparisons of heatmaps into one. The two heatmaps being merged 
have difference in the type of cell strain and share same cell type (CD4 or CD8) and gene list (up 
or down gene list). The merged heatmap contains all genes in either of the two comparisons. For 
each cell in the heatmap, we calculated the difference of cpm values between two strains of cell 
for one subject and divided by average cpm value of that gene in all three subjects. 
 
Data/Statistical Analysis 
Data are stored on a secure server at the University of Kansas Medical Center. Data were 
collected and analyzed with GraphPad Prism 7 (GraphPad Software, [La Jolla, CA]).  Data 
reported at each time point for GVHD score and weight loss were an average of the scores and 
weights of the mice left alive and the last scores and weights of any deceased mice in each 
group. Mann-Whitney tests were done to compare GVHD scores at each time point. The log-
rank (Mantel-Cox) test was used for analysis of Kaplan-Meier curves. Differences between 
groups were compared via Mann Whitney tests. Differences between groups with data 
normalized to a control were compared using the Wilcoxon test.  p≤0.05 was considered to be 





Dual retroviral transduction can convey FOXP3 and Helios expression in human T cells 
 In order to generate human eTregs that express both FOXP3 and Helios, we developed a 
dual transduction protocol. This was required as transduction of human T cells with a vector that 
contained both Helios and FOXP3 had downregulation of FOXP3 expression and the truncated 
ΔCD19 transduction marker (Figure 2-1A-B). There were multiple Helios binding sites present 
in the cDNA construct containing Helios and FOXP3 (data not shown) and Helios can 
downregulate gene expression upon binding [40]. With the dual transduction protocol, Helios-
overexpressing cells did not downregulate expression of the truncated ΔCD34 expression until 
about four days post-transduction (data not shown). We could use magnetic bead separation to 
purify Helios+ ΔCD34+ cells two days post-transduction and removed the magnetic beads. Then, 
we transduced these cells with the SFG-FOXP3-ΔCD19 retroviral vector and repeated magnetic 
bead purification to obtain human eTregs that highly expressed Helios and FOXP3 (Figure 2-
2B). In contrast to previously published eTreg studies, we transduced total human T cells rather 
than purified CD4+ T cells [32]. It has been demonstrated that Helios is required to mediate CD8 
Treg function [43]. Thus, we hypothesized that co-expression of FOXP3 and Helios could 
convey immunosuppressive function to human CD8+ T cells. Additionally, transduction of total 
T cells would reduce purification steps required to generate these eTregs in a clinical setting. 
Both CD4+ and CD8+ T cells within the total T cell population expressed high levels of Helios 
and FOXP3 (Figure 2-2B). We also chose to investigate the two different endogenous splice 
variants of Helios, Hel-FL and Hel-Δ3B, in eTreg function. RT-PCR gel electrophoresis showed 
that the overexpressed isoform of Helios was the predominant splice variant of Helios expressed 
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in each eTreg (Figure 2-2D). Thus, we generated eTregs strains that overexpress FOXP3, 
FOXP3+Hel-FL and FOXP3+ Hel-Δ3B and an empty vector control, ΔCD19+ΔCD34. 
 
FOXP3+Hel-FL eTregs delay disease in vivo in a xenoGVHD model 
 In order to assess the suppressive capacity of each eTreg cell strain in vivo, we utilized a 
xenogeneic Graft versus Host (xenoGVHD) disease model in which sublethally irradiated NSG 
mice were intravenously injected with human PBMCs without or with each eTreg cell strain or 
empty vector control cells.  Mice treated with FOXP3+Hel-FL eTregs had significantly delayed 
GVHD progression compared to mice with PBMCs only (Figure 2-3A). Additionally, 
FOXP3+Hel-FL eTregs significantly improved survival based on a log-rank test compared to 
mice with PBMCs only (Figure 2-3B). Mice treated with FOXP3+Hel-FL eTregs had a median 
survival of 36 days compared to mice with PBMCs only, which had a median survival of 21 
days. Interestingly, mice treated with FOXP3 or FOXP3+Hel-Δ3B eTregs did not significantly 
delay GVHD with median survivals of 27.5 days and 29 days respectively. 
 Next, irradiated NSG mice were injected with human PBMCs without or with each eTreg 
cell strain or empty vector control cells and euthanized at an early timepoint of 12 days to assess 
mice at different stages of disease. As observed in the long term xenoGVHD experiment, mice 
treated with FOXP3+Hel-FL had the lowest average GVHD score at this time point with a mean 
score of 0.6 ±0.4 compared to 2.8 ±0.86 for mice injected with PBMCs only (Figure 2-4A). 
Spleens from each mouse were processed into a single cell suspension and analyzed via flow 
cytometry. The number of total splenocytes was not significantly affected by eTreg treatment, 
but all three eTreg cell strains significantly decreased the percent of CD3+ CD19- non-
transduced T cells in the spleen (Figure 2-4B-C). Each eTreg also increased the percent of 
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FOXP3+ CD25hi and FOXP3+ Helios+ Tregs in the CD3+ CD19- non-transduced T cell 
population (Figure 2-4D). However, even though all three eTreg cell strains conveyed these 
immunosuppressive effects in the spleen, FOXP3+Hel-FL eTregs were still the most effective at 
delaying GVHD (Figure 2-4A).  
 Serum cytokines from these early time point mice were analyzed via cytometric bead 
array and revealed many differences between the treatment groups. Compared to the empty 
vector control treated mice, all three eTreg strains decreased multiple pro-inflammatory proteins 
in the serum, including IL-4, TNFα, sFas, sFasL, granzymes A and B, perforin and granylysin 
(Figure 2-5). Interestingly, both FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs decreased IL-6 
in the serum and FOXP3 and FOXP3+Hel-FL eTregs decreased IFNγ (Figure 2-5). Thus, 
FOXP3+Hel-FL eTregs could effectively delay disease and improve survival in a xenoGVHD 
model, while FOXP3 and FOXP3+Hel-Δ3B eTregs could not, but the mechanism was unclear.  
 
Hel-FL and Hel-Δ3B co-expression with FOXP3 differentially regulate CD4+ and CD8+ 
eTreg suppression 
 The ability of each eTreg strain to suppress T cell proliferation was also tested in vitro. In 
addition to total eTregs, CD4+ and CD8+ T cells were purified via magnetic bead separation and 
assayed separately. Freshly isolated human T cells were labeled with a proliferation dye and co-
cultured with each eTreg cell strain, total, CD4+ or CD8+, at a 1:1 ratio. Cells were stimulated 
with anti-CD3 and anti-CD28 coated beads for four days before being assayed via flow 
cytometry. In agreement with the in vivo data, FOXP3+Hel-FL total eTregs were the most 
effective at suppression compared with FOXP3 and FOXP3+Hel-Δ3B total eTregs, with a mean 
percent suppression of 46.21 ±12.54% vs 16.47 ±4.526% vs 21.67 ±8.658%, respectively 
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(Figure 2-6A). The same was true for CD4+ eTregs with FOXP3+Hel-FL suppressing 
proliferation at a mean of 40.82 ±10.36% compared to 21.19 ±8.968% and 19.06 ±8.968% 
suppression by FOXP3 and FOXP3+Hel-Δ3B CD4+ eTregs respectively (Figure 2-6A). 
However, both FOXP+Hel-FL and FOXP3+Hel-Δ3B overexpression in CD8+ eTregs was able 
to most effectively mediate suppression of T cell proliferation with a percent suppression of 
45.85 ±7.794% and 48.30 ±10.88%, respectively, compared to FOXP3 alone, which had a 
percent suppression of 21.68 ±11.01% (Figure 2-6A). In conclusion, CD4+ T cells transduced 
with FOXP3 and Hel-FL could were the most effective at suppressing T cells in vitro compared 
to FOXP3 and FOXP3+Hel-Δ3B. Both FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD8+ eTregs 
were more effective than FOXP3 CD8+ eTregs alone at suppressing T cell proliferation.  
 
Ectopic overexpression of FOXP3 without and with Helios reduces T cell survival in vitro and 
in vivo 
 Previous studies reported that overexpression of FOXP3 in primary human T cells 
reduced proliferation in vitro [32], and ectopic expression of Helios in Jurkat cells, a human T 
cell line, also resulted in reduced survival in vitro [44]. Thus, we analyzed the proliferation and 
survival of each eTreg cell strain. We observed that overexpression of FOXP3 in human T cells 
reduced proliferation over time and the addition of either isoform of Helios with FOXP3 
expression further reduced proliferation (Figure 2-7A). There was also an increase in activation-
induced cell death in all three eTreg cell strains, with more death observed in both the Helios-
expressing eTregs (Figure 2-7C). This decreased survival in all eTreg strains was observed in 
vivo in the xenoGVHD mice euthanized at an early time point. Flow cytometry of the spleen 
revealed a decrease in percent of CD3+ CD19+ transduced eTregs compared to empty vector 
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controls (Figure 2-7B). Digital drop PCR for copies of CD3 and the codon-optimized CD19, 
which is only present in the transduced cells, was performed on genomic DNA from lung, liver 
and spleen of xenoGVHD euthanized at an early timepoint. All eTreg treated mice had a reduced 
CD19/CD3 copy number ratio compared to empty vector control mice indicating a decrease of 
transduced cells detected in those tissues (Figure 2-7D). Thus, overexpression of FOXP3 
without or with either isoform of Helios reduces proliferation and survival of human T cells in 
vitro and in vivo. 
 
FOXP3 overexpression without and with Helios affects human T cell expression of Treg 
markers and cytokine production 
 Overexpression of FOXP3 in primary human T cells has been shown to mediate 
expression of Treg markers; specifically, increased expression of CD25, GITR, CTLA-4 and 
decreased expression of CD127 [32]. We used multi-parameter flow cytometry to analyze 
expression of the following Treg markers on all three eTreg cell strains: CD25, CD127, CD73, 
CD39, CTLA-4, GITR, CCR4 and CD62L. Human T cell surface expression of CD39, CTLA-4, 
GITR and CD62L was not significantly affected by FOXP3 overexpression without and with 
either isoform of Helios compared to empty vector control cells (data not shown). All three 
eTreg cell strains had significantly decreased CD127 expression on CD4+ eTregs and increased 
CCR4 expression on both CD4+ and CD8 eTregs (Figure 2-8A). CD25 was significantly 
increased for both CD4+ and CD8+ eTregs with FOXP3+Hel-FL and only CD8+ eTregs with 
FOXP3+Hel-Δ3B (Figure 2-8A). 
 Cytokine production by each eTreg cell strain was assessed via stimulation with plate 
bound anti-CD3 and anti-CD28 in the presence of Golgi transport inhibitors, Brefeldin A and 
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monensin. In agreement with previously published data, FOXP3 overexpression reduced 
production of IL-2, IFNγ and IL-4 by CD4+ human T cells [32]. FOXP3+Hel-FL and 
FOXP3+Hel-Δ3B eTregs also had a similar reduction in IL-2, IFNγ and IL-4 production by 
CD4+ T cells (Figure 2-8B). FOXP3 ectopic expression without and with either isoform of 
Helios also reduced IL-2 production by CD8+ (Figure 2-8C). In summary, transduced human T 
cells expressing FOXP3, FOXP3+Hel-FL or FOXP3+Hel-Δ3B upregulate certain Treg surface 
markers and have reduced pro-inflammatory cytokine secretion.  
 
Hel-FL and Hel-Δ3B co-expression with FOXP3 have different effects on the enrichment of 
genes in cellular pathways and Treg transcriptional signature  
 Despite the differences in immunosuppression observed between FOXP3+Hel-FL 
compared to FOXP3 and FOXP3+Hel-Δ3B in vitro and in vivo, there were no obvious 
differences between these cell strains with regards to proliferation and survival, Treg markers 
and cytokine secretion (Figures 2-7 and 2-8). Thus, we utilized RNA sequencing (RNA Seq) to 
determine if there were any differences between these eTreg cell strains at a transcriptional level. 
Three different healthy donor T cells were transduced with FOXP3, FOXP3+Hel-FL and 
FOXP3+Hel-Δ3B. Then CD4+ and CD8+ T cells from each eTreg cell strain were separated via 
fluorescence-activated cell sorting (FACS). RNA was extracted from each sample and analyzed 
via RNA Seq.  
Comparison of gene expression fold change revealed that adding either isoform of Helios 
to FOXP3-overexpressing CD4+ and CD8+ eTregs did change gene expression compared to 
FOXP3 alone (Figure 2-9A). We then carried out Gene Set Enrichment Analysis (GSEA) 
pathway analysis using GSEA v3.0 from the Broad Institute and the Kyoto Encyclopedia of 
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Genes and Genomes (KEGG) database. Both FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD4+ and 
CD8+ eTregs had changes in pathway enrichment when compared to FOXP3 alone (Figure 2-
9B). Notably, there were more increases in pathway enrichment in the FOXP3+Hel-Δ3B vs 
FOXP3 comparison compared to the FOXP3+Hel-FL vs FOXP3 comparison in both CD4+ and 
CD8+ eTregs.  
Expectedly, there were fewer differences in gene expression when comparing 
FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs (Figure 2-10A). Despite the small differences in 
gene expression, FOXP3+Hel-FL had different enriched KEGG pathways when compared to 
FOXP3+Hel-Δ3B in both CD4+ and CD8+ eTregs (Figure 2-10B). Three of these enriched 
pathways were the same in CD4+ and CD8+ FOXP3+Hel-FL eTregs: p53 signaling pathway, 
cell adhesion molecules and cytokine-cytokine receptor interaction.  Interestingly, some of the 
genes that were changed in these two common pathways did differ between CD4+ and CD8+ 
eTregs (Figure 2-10C).  
In order to determine changes in Treg-related genes in the eTreg cell strains, we 
generated lists of genes based on comparisons of Tconvs vs Tregs generated by Miyara et al., 
Mold et al. and Bonacci et al. [133, 346, 347]. We compiled genes that were either up-regulated 
or down-regulated in Tregs compared to Tconvs, named the “TREG UP” and “TREG DOWN” 
gene lists respectively. We then analyzed whether adding Hel-FL or Hel-Δ3B to FOXP3-
overexpressing eTregs led to up-regulation of the TREG UP genes and down-regulation of the 
TREG DOWN genes, indicating an increase in Treg signature. Interestingly, FOXP3+Hel-Δ3B 
had more genes in the Treg signature that were differentially expressed than FOXP3+Hel-FL 
when compared to FOXP3. This was true for both CD4+ and CD8+ eTregs. Additionally, there 
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were many Treg genes that were only differentially expressed in either FOXP3+Hel-FL or 
FOXP3+Hel-Δ3B when compared to FOXP3 in both CD4+ and CD8+ eTregs. 
In summary, Hel-FL or Hel- Δ3B co-expression with FOXP3 in CD4+ and CD8+ eTregs 
changed gene expression when compared to FOXP3 and this led to changes in gene enrichment 
of cellular pathways. Hel-Δ3B had more instances of increased enrichment of pathways than 
Hel-FL when co-expressed with FOXP3 in CD4+ and CD8+ eTregs. Additionally, there were 
differences in gene expression and pathway enrichment when directly comparing FOXP3+Hel-
FL and FOXP3+Hel-Δ3B eTregs and some gene changes were different between CD4+ vs CD8+ 
eTregs from the same eTreg cell strain. Finally, FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD4+ 
and CD8+ eTregs had increased changes in Treg signature genes compared to FOXP3 alone. 
Some of these genes were unique to either FOXP3+Hel-FL or FOXP3+Hel-Δ3B. FOXP3+Hel-




Figure 2-1: Helios overexpression downregulates expression of cDNA on the same vector. 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy blood donors. T cells 
were activated with anti-CD3 and anti-CD28 antibody stimulation, cultured in IL-2 containing 
media and transduced with retroviral particles containing cDNA for genes of interest. The cDNA 
on these cells were expressed on a single SFG retroviral vector. Transduced cells were purified 
with antibody-coated magnetic bead particle separation specific for the transduction marker 
ΔCD19. A) Representative dot plots of CD19 and FOXP3 expression for FOXP3, FOXP3-Hel-
FL and FOXP3-Hel-Δ3B eTregs B) Graphs summarize the geometric mean fluorescence 
intensity (GMFI) of FOXP3 and CD19 of the indicated eTreg population normalized to empty 











Figure 2-2: Retroviral transduced human T cells express FOXP3 and/or Helios. Peripheral 
blood mononuclear cells (PBMCs) were isolated from healthy blood donors. T cells were 
activated with anti-CD3 and anti-CD28 antibody stimulation, cultured in IL-2 containing media 
and transduced with retroviral particles containing cDNA for genes of interest. Transduced cells 
were purified with antibody-coated magnetic bead particle separation specific for transduction 
surface markers. A) Illustration of SFG retroviral vector containing genes of interest and 
transduction surface markers. Helios and FOXP3 protein expression in B) CD4+ eTregs and C) 
CD8+ eTregs were assessed via intracellular transcription factor staining and flow cytometry. 
Dot plots are representative figures and graphs summarize the geometric mean fluorescence 
intensity (GMFI) of FOXP3 and Helios of the population positive for the protein of interest, 
N=8-9 and 5 different donors. D) Representative figure of Helios mRNA expression assessed via 







Figure 2-2: Retroviral transduced human T cells express FOXP3 and/or Helios. 
Figure 2-3: FOXP3 + Hel-FL eTregs delay disease progression in a xenogeneic GVHD 
murine model. 8-12 week old NSG mice were sub-lethally irradiated. The next day, the mice 
were injected retro-orbitally with 107 human PBMCs alone or with 5x106 empty vector control 
cells or eTregs. A) GVHD score was monitored until day of sacrifice. *= p<0.05 compared to 
PBMCs only based on a one-tailed Mann-Whitney test for each time point. B) Kaplan-Meier 
curve of survival. Death was marked when GVHD score was 7.  *= p<0.05 compared to 









Figure 2-4: FOXP3+Helios-FL overexpression in T cells reduces inflammation in 
xenoGVHD mice at an early timepoint. 8-12 week old NSG mice were sub-lethally irradiated. 
The next day, the mice were injected retro-orbitally with 107 human PBMCs alone or with 5x106 
empty vector control cells or eTregs. A) GVHD score was monitored until day of sacrifice. Mice 
were all euthanized at an early time point of 12 days and spleens were isolated, processed into a 
single cell suspension, labeled with antibodies for flow cytometry and analyzed for B) number of 
total splenocytes, C) percent of CD3+ CD19- responder T cells and D) percent of Tregs within 
the CD19- responder T cell population. Tregs were defined as CD3+ CD4+ CD25+ FOXP3+ or 
CD3+ CD4+ CD25+ FOXP3+ Helios+. N=3-5 for each group and *= p<0.05 compared to 










Figure 2-5: eTreg treatment of xenoGVHD mice reduces pro-inflammatory proteins in the 
serum. 8-12 week old NSG mice were sub-lethally irradiated. The next day, the mice were 
injected retro-orbitally with 107 human PBMCs alone or with 5x106 empty vector control cells or 
eTregs. Mice were all euthanized at an early time point of 12 days and serum was isolated from 
blood recovered post-mortem. Soluble proteins were quantified using cytometric bead array. 





Figure 2-5:  eTreg treatment of xenoGVHD mice reduces pro-inflammatory  proteins in the serum. 
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Figure 2-6: FOXP3+Hel-FL and FOXP3+Hel-Δ3B differentially mediate CD4+ and CD8+ 
eTreg suppression. Labeled autologous target Tconv cells were co-cultured with each eTreg cell 
strain or empty vector control cells with no stimulation or stimulation with anti-CD3 and anti-
CD28 coated beads. CD4+ and CD8+ eTregs and empty vector cells were purified via antibody 
coated magnetic bead separation. Cells were plated at effector to target ratios of 1:1. After 96 
hours, target cell proliferation was assayed via flow cytometry. A) Percent suppression for each 
eTreg cell strain. N=5-7 for each group with 4 different donors. Percent suppression is calculated 
by the following equation: [(percent responder proliferation alone)-(percent responder 
proliferation with transduced cells)]/ (percent responder proliferation alone) x 100. *= p<0.05 
compared to empty vector control based on a one-tailed Wilcoxon test. B) Representative dot 











Figure 2-7: FOXP3, FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs have reduced 
proliferation and survival. A) Cell counts of eTregs growing in IL-2 supplemented media were 
collected over 9 days. N=4 for each group from 4 different donors. *= p<0.05 compared to 
empty vector control based on a one-tailed Mann-Whitney test for each time point. B) Frequency 
of transduced eTregs in the spleens of xenoGVHD mice sacrificed day 12 post-injection via flow 
cytometry. Mice were treated as previously described. Transduced eTregs and empty vector 
control cells were identified as CD3+ CD19+ via flow cytometry. C) eTregs were stimulated for 
2, 4 and 6 days with anti-CD3 and anti-CD28 plate bound antibody. Numbers of live cells per µL 
were assessed via flow cytometry. Live cells were defined as Zombie Green and Annexin V 
negative cells. N=5-6 from 4-6 different donors for each group. *= p<0.05 compared to empty 
vector control based on a one-tailed Mann-Whitney test. D) Copy number of CD19/Copy 
number of CD3 to detect transduced eTregs or empty vector control cells in tissues from 
xenoGVHD mice sacrificed day 12 post-injection via flow cytometry. Genomic DNA was 
isolated from each tissue and digital drop PCR was used to quantify CD19 copy numbers and 
CD3 copy numbers. Primers for CD19 were specific for codon optimized CD19 that was only 







Figure 2-7: FOXP3, FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs have reduced proliferation and surv ival.  
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Figure 2-8: FOXP3, FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs express regulatory T 
cell markers and have reduced cytokine production. A) Expression of Treg markers by CD4+ 
and CD8+ eTregs. Marker expression was assessed via flow cytometry and plotted as geometric 
mean fluorescence intensity (GMFI) of the population positive for the marker. N=3-7 and 5 
different donors. *= p<0.05 compared to empty vector control based on one-tailed Mann-
Whitney test. B) Cytokine production by CD4+ and CD8+ eTregs. eTregs were stimulated for 6 
hours with anti-CD3 and anti-CD28 plate bound antibody and Brefeldin A and Golgi Stop. Cells 
were assessed for cytokine production via intracellular cytokine staining and flow cytometry. 
Values normalized to empty vector control and N=4-9 with 4-6 different donors for each group. 






   
Figure 2-8: FOXP3, FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs express regulatory T cell markers 
and have reduced cytokine production. 
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Figure 2-9: Hel-FL or Hel-Δ3B co-expression with FOXP3 alters gene expression and 
pathway enrichment in CD4+ or CD8+ eTregs compared to FOXP3 alone. All comparisons 
in this figure use FOXP3 eTregs as the baseline for comparison of CD4+ or CD8+ eTregs as 
indicated. A) Volcano plots depicting -log10p-value versus log Fold Change (FC). Within the 
volcano plots, genes were colored if they had a nominal, uncorrected p value less than 0.05. Blue 
color denotes down regulation while red color represents up regulation. The two vertical lines 
represent logFC = -2 and logFC=2. The horizontal line presents -log10(0.05).  B) Summary of 
normalized enrichment scores (NES) of KEGG pathways with p<0.05 that were enriched in the 
comparison of two eTreg cell strains indicated following gene set enrichment analysis (GSEA). 
Blue bars are pathways enriched in the baseline eTregs and red bars are pathways enriched in 






Figure 2-9: Hel- FL or Hel-Δ3B co-expression w ith FOXP3 alters gene expression and pathway  enrichment in CD4+ or CD8+ eTregs compared to FOXP3 alone.  
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Figure 2-10: FOXP3+Hel-Δ3B mediates different gene transcription and pathway 
enrichment in CD4+ and CD8+ eTregs compared to FOXP3+Hel-FL. All comparisons in 
this figure use FOXP3+Hel-FL eTregs as the baseline for comparison, either CD4+ or CD8+ as 
indicated. A) Volcano plots depicting -log10p-value versus log Fold Change (FC). Within the 
volcano plots, genes were colored if they had a nominal, uncorrected p value less than 0.05. Blue 
color denotes down regulation while red color represents up regulation. The two vertical lines 
represent logFC = -2 and logFC=2. The horizontal line presents -log10(0.05).   B) Summary of 
normalized enrichment scores (NES) of KEGG pathways with p<0.05 that were enriched in 
comparisons of two eTreg cell strains following gene set enrichment analysis (GSEA). Blue bars 
are pathways enriched in the baseline eTregs and red bars are pathways enriched in eTregs being 
compared. C) Heatmaps of genes altered in common pathways enriched in CD4+ and CD8+ 






Figure 2-10:  FOXP3+Hel-Δ3B mediates different gene transcription and pathway  enrichment in CD4+ and CD8+ eTregs compared to FOXP3+Hel-FL.  
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Figure 2-11: Hel-FL or Hel-Δ3B co-expression with FOXP3 mediate different gene 
transcription of Treg signature genes in CD4+ and CD8+ eTregs. Heatmaps comparing 
expression of Treg signature genes that are A) upregulated in Tregs (TREG UP) or B) 
downregulated in Tregs (TREG DOWN) compared to Tconv. Each heatmap shows differential 
expression of genes in each of the three donors for FOXP3 vs FOXP3+ Hel-FL (FL, donors FL1-
FL3) and FOXP3 vs FOXP3+ Hel-Δ3B (Δ3B, donors Δ3B1-Δ3B1) in both CD4+ and CD8+ 
eTregs as indicated. For each cell in the heatmap, the difference of cpm values between two 










Here we described a dual retroviral transduction system that was able to overexpress 
FOXP3+Hel-FL in total human T cells and convert these T cells into CD4+ and CD8+ eTregs 
with immunosuppressive properties both in vitro and in vivo. Additionally, we are the first to 
describe differential roles for the two endogenous isoforms of Helios in mediating suppressive 
function in CD4+ and CD8+. Finally, we provided transcriptional profiling of human eTregs that 
expressed FOXP3, FOXP3+Hel-FL and FOXP3+Hel-Δ3B and compared these profiles to 
KEGG pathways and published Treg signatures. Together, these findings not only provide 
insight into the role of Helios and FOXP3 co-expression in Treg function but improve current 
human eTreg generation protocols and increase the potential for eTregs to be used in the clinic.  
 Helios has been described as a key Treg transcription factor for many years but its 
function in Tregs is still being defined. Experiments using Treg-specific Helios knock out mice 
have demonstrated that Helios plays a major role in mediating both CD4+ and CD8+ Treg 
function and survival [42, 43]. The Helios+ subset of human CD4+ Tregs have improved 
stability in pro-inflammatory environments compared to Helios- CD4+ Tregs [42, 43]. A subset 
of Helios+ CD8+ Tregs have also been defined and have been shown to target T follicular helper 
cells [192]. Our work demonstrated that co-expression of FOXP3 with Hel-FL in total human 
cells was able to more effectively delay disease in a xenoGVHD model compared to FOXP3 
alone. Both CD4+ and CD8+ FOXP3+Hel-FL eTregs had the most suppressive capacity in vitro 
compared to FOXP3 alone. However, there were no obvious differences in survival, Treg marker 
expression or cytokine production (Figures 2-7 and 2-8). There was a change in FOXP3+Hel-
FL eTregs in expression of genes compared to FOXP3 alone in immune pathways, such as cell 
adhesion molecules and JAK/STAT signaling, and Treg-related genes. This change in 
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transcription was expected as ectopic expression of Helios and FOXP3 separately and together in 
mouse Tconvs mediated expression of different Treg signature genes [277, 298]. Further studies 
will be needed to investigate the roles of the genes altered by Hel-FL expression in Treg 
function.  
An unexpected result was the differences between FOXP3+Hel-FL and FOXP3+Hel-
Δ3B eTreg function. To the best of our knowledge, there have been no studies comparing the 
function of Hel-FL and Hel-Δ3B in primary human T cells. We demonstrated that FOXP3+Hel-
FL overexpression improves CD4+ eTreg suppressive activity, FOXP3+Hel-Δ3B overexpression 
does not. Interestingly, FOXP3+Hel-Δ3B does improve suppressive activity of CD8+ eTregs to a 
similar degree as FOXP3+Hel-FL eTregs. Both Hel-FL and Hel-Δ3B co-expression with FOXP3 
changed gene expression when compared to FOXP3 alone and there were changes that were 
unique to each isoform of Helios.  
Correlation of the gene changes in FOXP3+Hel-FL and FOXP3+ Hel-Δ3B with our 
functional studies could reveal more about the molecular mechanisms required to convey 
immunosuppressive properties to CD4+ and CD8+ T cells. For example, our RNASeq and 
GSEA data showed that FOXP3+Hel-FL CD4+ eTregs had increased gene enrichment in p53 
signaling and cytokine-cytokine receptor interaction and decreased gene enrichment in cell 
adhesion molecules (CAMs) when compared to FOXP3+Hel-Δ3B CD4+ eTregs (Figure 2-10B). 
p53 signaling is important for CD4+ Treg induction in mice [348]. The different cytokine 
receptors that were upregulated on FOXP3+Hel-FL CD4+ eTregs were chemokine receptors 
such as CCR5 and CXCR6 which have been demonstrated to be expressed on endogenous 
human Tregs [349] and these receptors drive immune cell trafficking to sites of inflammation 
[350-353].  Finally, the only CAM that has been extensively studied in Treg function is ICAM-1 
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which is not differentially expressed in FOXP3-Hel-FL vs FOXP3-Hel-Δ3B CD4+ eTregs 
(Figure 2-10C) [354, 355].  The differences we observed in CAM expression between 
FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD4+ eTregs could be linked to T cell 
immunosuppressive function, though further studies are needed. Thus, the changes we found in 
these three KEGG pathways could explain why FOXP3+Hel-FL CD4+ eTregs were more 
effective at suppressing in vivo and in vitro than FOXP3+Hel-Δ3B CD4+ eTregs.  
The same three pathways were also changed in FOXP3+Hel-Δ3B CD8+ compared to 
FOXP3+Hel-FL CD8+ eTregs but these two eTreg cell strains suppress equally well. Further 
examination revealed there were differences in the specific genes that were changed in these 
three pathways when comparing CD4+ and CD8+ FOXP3+Hel-Δ3B eTregs (Figure 2-10C).  
Thus, the specific gene expression differences in these pathways that were unique to the CD4+ 
eTregs could identify the genes important in mediating T cell suppressive activity. Alternatively, 
CD8+ eTregs might not require these three pathways to suppress. Additionally, we found that 
both CD4+ and CD8+ FOXP3+Hel-Δ3B had a higher Treg signature compared to FOXP3+Hel-
FL eTregs based on the number of genes that were differentially expressed in our Treg signature 
gene lists. However, based on the functional differences between FOXP3+Hel-FL and 
FOXP3+Hel- Δ3B CD4+ eTregs, it is likely the genes that are differentially expressed between 
these two eTreg cell strains that are critical to CD4+ T cell immunosuppressive function rather 
than the number of genes changed. Similarly, the gene expression differences between the 
FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD8+ eTregs may not be critical to CD8+ T cell 
immunosuppression as these two cell strains suppress at a similar level.  
These findings indicate that the endogenous isoforms of Helios play different roles in 
CD4+ vs CD8+ T cells. Hel-Δ3B lacks half an exon in a zinc finger domain, which would affect 
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its ability to bind DNA. Thus, differences between the effect of FOXP3+Hel-Δ3B 
overexpression in CD4+ vs CD8+ T cells likely arises from epigenetic differences between the 
cell subsets and promoter accessibility. Another example of Ikaros family members playing 
different roles in CD4+ and CD8+ T cells is the critical role of Ikaros in CD8+ T cell 
development but not CD4+ development [356]. Investigating the differences between FOXP3, 
FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD4+ and CD8+ eTregs could help define which 
signaling pathways are critical for CD4+ and CD8+ Treg function. Further studies are required to 
elucidate the roles of these Helios splice variants in general T cell development and function. 
 Overall, we generated a novel protocol to genetically manipulate human T cells to 
express high levels of FOXP3+Hel-FL, which results in immunosuppressive CD4+ and CD8+ 
eTregs. FOXP3+Hel-FL eTregs are more effective than FOXP3 eTregs at suppressing both in 
vivo and in vitro and have changes in gene expression that affect immune pathway and Treg 
signature genes. We also discovered that Hel-FL and Hel-Δ3B affect CD4+ and CD8+ T cells 
differently when co-expressed with FOXP3. These new findings define new roles for 
endogenous Helios splice variants in both CD4+ and CD8+ Tregs and provide an improved 





Chapter 3 : Expression profiling of Ikaros family members and Treg markers in thymic 
CD4+ regulatory T cell development in the CD4+ mature single positive stages 
Abstract  
Regulatory T (Tregs) are a subset of immune cells that maintain homeostasis by 
promoting immune tolerance and suppressing the immune response via a variety of mechanisms 
such as secreting cytokines, killing reactive immune cells, and inducing anergy. Tregs have 
proven to be difficult to study as there are no definitive Treg surface markers. Analysis of the 
expression of members of the Ikaros family of transcription factors during Treg development can 
aid in defining Treg surface markers. Here, we used novel CD4+ mature single positive (MSP) 
thymocyte populations that our laboratory has previously defined to track CD4+ CD25+ 
FOXP3+ human Treg development from human thymus samples. We then characterized protein 
expression of Ikaros family members and Treg markers of Tregs from each of these populations. 
We found that a majority of Tregs can be found in the distinct MSP6 population and these Tregs 
have heterogenous expression of Helios and CD39 and CD127. Within the MSP1-MSP5 
populations expression of Ikaros family members transiently changed and Helios and Eos 
correlated with the percent of Tregs within each population. Thus, using Ikaros family members 
and Treg markers within subsets of CD4+ thymocytes, we were able to more precisely determine 









Regulatory T (Treg) cells are approximately 3-5% of CD4+ T cells and function to 
promote immune tolerance and maintain immunologic homeostasis.  Detailed mechanisms by 
which Tregs down-regulate immune responses vary and have been reviewed elsewhere [34], but 
include secreting IL-10 and TGF, which suppress the proliferation and activation of pro-
inflammatory conventional T (Tconv) cells [33].  Tregs can also convert ATP into the 
immunosuppressive molecule adenosine and modulate metabolic activity [252].  Beyond their 
activities on other T cells, Tregs can directly interact with dendritic cells and downregulate co-
stimulation of Tconv cells [357]. Tregs can also suppress macrophages and B cells[358-360]. 
Impaired Treg numbers or function has been linked to overactive immune responses, 
which contributes to diseases such as autoimmunity, allergy, and graft-versus-host disease [361-
363].  Conversely, tumors often contain numerous Tregs that suppress anti-tumor immunity 
[364].  Thus, the ability to manipulate the number or function of Tregs would have profound 
therapeutic effects.  For example, injection of Tregs has been successfully used in murine models 
of multiple sclerosis, inflammatory bowel disease, and graft-versus-host disease [289, 365, 366].  
However, translating these results into the clinic has been challenging, despite many attempts. 
One challenge faced in Treg therapy has been to accurately identify this small cell 
population.  Tregs are characterized by high expression of the FOXP3 transcription factor.  In 
addition, Tregs express CD25, GITR, and CTLA-4, but low levels of CD127.  In humans, these 
markers can also define activated T cells [22], making the isolation of a pure Treg population 
nearly impossible.  Further, Tregs can differentiate into pro-inflammatory CD4+ T cells under the 
appropriate conditions [198], so a pure Treg population could become a mixed population due to 
the plasticity of the differentiation state. 
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A potential solution to the problem of obtaining a pure, stable Treg population is to 
isolate Tregs from the thymus instead of peripheral blood.  Dijke, et. al. [289] showed that 
thymic-derived Tregs were more effective than Tregs obtained from peripheral blood in 
preventing graft-versus-host disease in a murine model of the disease.  The most likely reason for 
the difference in efficacy is the stability of thymic Treg function, even in the presence of pro-
inflammatory cytokines.  These data demonstrate the value in identifying the characteristics that 
define thymic Tregs and explain the stability of this population.  
One defining feature of thymic Tregs is their high expression of Helios, a member of the 
Ikaros family transcription factors.  In addition, Tregs can express Ikaros, Aiolos, and Eos.  Each 
Ikaros family member has four DNA-binding zinc finger motifs near the N-terminus and two C-
terminal zinc fingers that mediate protein-protein interactions [367].  Each family member can 
homodimerize or heterodimerize via the C-terminal zinc fingers in every possible combination 
[287, 367-370].  To further complicate this family of proteins, each member can undergo 
alternative splicing that eliminates one or more of the N-terminal zinc fingers [371-373].  
Deletion of more than two zinc fingers results in a dominant negative form of the protein that can 
dimerize with other family members but cannot bind DNA [367]. Examining the entire Ikaros 
family in Tregs offers a tool analyze Treg development and function. Here, we described protein 
expression of the Ikaros family in human CD4+ CD25+ FOXP3+  Tregs as they progress 
through the CD4+ mature single positive (MSP) stages that we have previously described [77]. 






Human thymus samples were obtained, following informed consent of the parent or 
guardian, from children (0–18 years) who underwent corrective surgery for congenital cardiac 
defects at Children's Mercy Hospital (Kansas City, MO). Tissue samples were de-identified and 
void of any clinical data. Samples were obtained in compliance with the Institutional Review 
Boards at our institutions. Representative figures are from one thymus and multiple thymi from 




The anti‐human antibodies, anti‐CD3−APC-Cy7, anti‐CD7‐FITC, anti‐CD8α‐Brilliant 
Violet (BV) 785, anti‐CD25‐PerCP‐Cy5.5, anti‐CD38‐Alexa Fluor (AF) 700, anti‐CD44‐PE‐
Cy7, anti‐CD45RO‐PE‐Cy5, anti‐FOXP3‐AF647, anti‐Helios‐BV421, anti-CD39-BV510, anti-
CD127-BV650, Armenian hamster IgG‐BV421 control and mouse IgG1κ‐PE control were 
purchased from Biolegend (San Diego, CA). Anti‐CD4‐PE‐eFlour 610, was purchased from 
ThermoFisher Scientific (Waltham, MA), and anti-Eos-PE, anti‐Ikaros‐PE, anti‐Aiolos‐PE and 
mouse IgG1κ‐PE control were purchased from BD Biosciences (San Jose, CA). 
Single‐cell suspensions of human thymocytes were labeled on their surface as previously 
described [374]. For intracellular staining, surface‐labelled cells were fixed and permeabilized 
using the Foxp3/Transcription Factor Staining Buffer Set from ThermoFisher Scientific 
(Waltham, MA), according to the manufacturer's instructions. Cells were analyzed using a BD 
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LSR II (BD Biosciences) and data were analysed using BD FACSdiva software (BD 
Biosciences) or FlowJo (TreeStar Inc., Ashland, OR).  
 
Statistical analysis 
For comparisons across groups, the paired t‐test analysis and multiple comparisons 
analysis with Tukey post hoc test were performed using Graphpad Prism 6 (GraphPad Software 





CD4+ CD25+ FOXP3+ Tregs are most frequent in the CD4+ MSP3-MSP5 and MSP6 
populations. 
 Current thymic Treg studies use CD4+ CD25+ expression to isolate thymic Tregs that 
have about 50% FOXP3 expression initially and about 80% FOXP3 expression after culture 
[289]. We first determined where these CD4+ CD25+ FOXP3+ were most abundant within the 
CD4+ MSP stages that we defined in our previous publication [77]. Briefly, these populations 
were defined as CD4+ single positive (SP) thymocytes that have high CD3 expression, 
indicating they are undergoing positive selection [375, 376]. 6 distinct populations, MSP1-
MSP6, fit these criteria and were defined based on their expression of CD7, CD44, CD38 and 
CD45RO (Figure 3-1). The sequence of these stages was determined based on CD38 and 
CD45RO expression as we previously observed that CD38 and CD45RO decreases as CD3hi 
populations mature based on surface activation marker expression [77]. MSP6 cells did not fit 
these criteria as these cells had increased expression of maturation and activation markers, low 
CD38 expression but high CD45RO. Thus, the MSP6 population was excluded from the MSP 
developmental stages and will be referred to as a separate thymocyte population in this study. 
Upon analysis of the percent of each MSP population that expressed CD25 and FOXP3, the 
highest percentages of Tregs was found in the MSP3-MSP5 and MSP6 populations, 8.343 ± 
2.518%, 3.485 ± 0.6756%, 4.630 ± 0.5003% and 50.95 ± 5.503% respectively (Figure 3-2). The 
high percentage of CD4+ CD25+ FOXP3+ T cells in the MSP6 population was unexpected as 
MSP6 cells only consist of 2.038 ± 0.6633% of CD4+ CD3hi CD7hi thymocytes.  
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Ikaros family member expression changes in CD4+ CD25+ FOXP3+ Tregs as they develop 
through the CD4+ MSP1-MSP5 developmental stages and have altered expression in the 
MSP6 population. 
 Next, we examined the intracellular protein expression levels of Helios, Eos, Aiolos and 
Ikaros in CD4+ CD25+ FOXP3+ Tregs within each MSP population. As the Tregs progress 
through the MSP1-MSP5 populations, Helios, Eos and Aiolos increase and then decrease 
(Figure 3-3). Ikaros levels slightly increase and then slightly decrease as Tregs move from 
MSP1 to MSP5 stages. In the MSP6 population, Helios, Aiolos and Ikaros are relatively 
unchanged in Tregs compared to Tregs in the MSP5 population. Interestingly, the decrease in 
Helios GMFI in the MSP6 Tregs is due to a split into Helios- and Helios+ populations rather 
than an overall decrease in expression of the whole population. Eos is increased in MSP6 Tregs 
compared to MSP5 Tregs. Thus, in the Tregs within the MSP1-5 populations, Helios, Eos and 
Aiolos expression changes in similar pattern while Ikaros gradually declines. The Tregs in the 
MSP6 population have similar expression of Helios, Aiolos and Ikaros as MSP5 but an increase 
in Eos.  
 
The Treg markers CD39 and CD127 have the highest expression on CD4+ CD25+ FOXP3+ 
Tregs in the MSP6 population. 
 We chose to examine two markers of Tregs, CD39 and CD127. It has been reported that 
CD39+ Tregs and CD127- Tregs could be found within human CD4+ SP thymocyte population 
[62, 63, 377, 378]. CD39+ Tregs were found within all the MSP1-MSP5 populations ranging 
from 6.375 ± 4.725% on MSP1 Tregs to 21.65 ± 8.362% on MSP5 Tregs (Figure 3-4A). CD39 
expression only slightly increased as Tregs progressed through these populations with average 
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CD39 GMFI of 381.0 ± 135.8 on MSP1 Tregs and 425.8 ± 49.36 on MSP5 Tregs (Figure 3-4B-
C).  CD127 was not completely absent on MSP1-MSP5 Tregs with a small percentage of 
CD127+ cells in each subset ranging from 16.73 ± 0.8616% on MSP4 Tregs to 38.93 ± 7.005% 
on MSP5 Tregs (Figure 3-4A). There was a slight increase, decrease and then another increase 
in CD127 expression as Tregs progressed from MSP1 to MSP5 stages with an average GMFI of 
764.3 ± 112.2 on MSP1 Tregs and 425.8 ± 269.2 on MSP5 (Figure 3-4B-C). Interestingly, 
CD39 and CD127 had very high expression on MSP6 Tregs with an average CD39 GMFI of 
6155 ± 3127 and average CD127 GMFI of 1547 ± 197.2 (Figure 3-4B-C). Further evaluation of 
CD39 and CD127 expression on the MSP6 Tregs reveal distinct populations of CD39+ CD127+ 
and CD39- CD127+ (Figure 3-4D).  Thus, CD39 and CD127 expression increased on Tregs 
from MSP1 to MSP5 stages and had the highest expression on MSP6 Tregs. The MSP6 Tregs 




Figure 3-1: Description and flow cytometry gating scheme of CD4+ MSP populations. A) 
Summary of markers defining CD4+ MSP1-MSP6 populations. Modified and printed with 
permissions from Mitchell, J.L., A. Seng, and T.M. Yankee, Expression patterns of Ikaros family 
members during positive selection and lineage commitment of human thymocytes. Immunology, 






Figure 3-1: Descrip tion and f low cy tometry  gating scheme of CD4+ MSP populations.  
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Figure 3-2: Frequency of CD4+ CD25+ FOXP3+ Tregs are highest in CD4+ MSP3-MSP5 
and MSP6 populations. Thymocytes were labeled with fluorophore-labeled antibodies 
extracellularly and intracellularly and analyzed via flow cytometry.  A) Summary of percent of 
CD4+ CD25+ FOXP3+ Tregs in each CD4+ MSP population. N=4. B) Representative contour 








Figure 3-3: Expression of Ikaros family members change in CD4+ CD25+ FOXP3+ Tregs 
in each CD4+ MSP population. Surface stained thymocytes were intracellularly stained with 
anti‐Helios, anti‐Aiolos, anti-Eos or anti-Ikaros antibodies. A) Summary of the geometric mean 
fluorescence (GMFI) of Helios, Eos, Aiolos or Ikaros in the CD4+ CD25+ FOXP3+ Tregs in 
each CD4+ MSP population. N=4. p<0.05 of sample compared to MSP1 following paired t‐test 
analysis and multiple comparisons analysis with Tukey post hoc test. B) Representative 
histogram of Helios, Eos, Aiolos or Ikaros expression in the CD4+ CD25+ FOXP3+ Tregs in 
each CD4+ MSP population. The Y-axis of each histogram is on the modal setting which scales 
all channels as a percentage of the maximum count. Black lined graphs represent the thymocytes 
stained with the antibody of interest and gray shaded graphs represent the appropriate IgG 





Figure 3-3: E xpression of Ikaros family  members change in CD4+ CD25+ FOXP3+ Tregs in each CD4+ MSP population.  
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Figure 3-4: Expression of the Treg markers CD39 and CD127 is the highest in the MSP6 
population. Surface stained thymocytes were analyzed via flow cytometry. Summary of the A) 
Percent positive and B) geometric mean fluorescence (GMFI) of CD39 and CD127 in the CD4+ 
CD25+ FOXP3+ Tregs in each CD4+ MSP population. N=4. C) Representative histogram of 
CD39 or CD127 expression on the CD4+ CD25+ FOXP3+ Tregs in each CD4+ MSP 
population. The Y-axis of each histogram is on the modal setting which scales all channels as a 
percentage of the maximum count. Black lined graphs represent the thymocytes stained with the 
antibody of interest and gray shaded graphs represents unstained thymocytes. D) Representative 











 The data presented here characterized expression patterns of Ikaros family members and 
Treg markers on CD4+ CD25+ FOXP3+ human Tregs found within novel CD4+ CD3hi MSP 
subsets we previously described [77] and a small MSP6 population that doesn’t fit within these 
developmental stages. We report that CD4+ CD25+ FOXP3+ T cells are most abundant in the 
MSP3-5 and MSP6 populations. There is a transient increase in Helios, Eos and Aiolos and 
slight decrease in Ikaros expression as the Tregs move through the MSP1-MSP5 stages. There is 
low expression of both the Treg markers CD39 and CD127. The MSP6 Treg population had 
distinct Ikaros family and CD39 and CD127 expression compared to the MSP1-MSP5 thymocyte 
populations. This is interesting as the majority of the CD4+ CD3hi CD25+ FOXP3+ T cells are 
derived from the MSP6 population.     
 Within the MSP1-MSP5 populations, the transient increase in Helios and Aiolos and the 
slight decrease in Ikaros in Tregs was similar to the changes we previously reported for the 
overall MSP populations and not unique to the Tregs. The transient increase in Eos was a novel 
finding and this transient increase is also found int the overall MSP populations as well (data not 
shown). MSP6 Tregs had high Eos expression relative to the MSP1-MSP5 Treg populations and 
had two distinct Helios+ and Helios- populations. The changes in the Ikaros family members in 
the Tregs could be significant as both Helios and Eos play major roles in inducing and 
maintaining Treg phenotype. Helios maintains FOXP3 and CD25 expression via the IL-2Rα-
STAT5 pathway [43]. Eos directly binds FOXP3 which leads to downstream suppression of 
genes such as Il2 and Ifng which conveys an immunosuppressive phenotype [285]. Thus, the 
increase of Helios in Tregs in the MSP3 and MSP4 populations could explain the increase 
CD25+ FOXP3+ cells in these populations. Additionally, increased expression of Eos in MSP3 
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and MSP4 Tregs could be important in Treg development. Overall, further studies of the role of 
Helios and Eos in Treg development could aid in defining Treg lineage commitment.    
 We found distinct expression of the Treg markers CD39 and CD127 in the MSP1-MSP5 
and MSP6 Treg populations. In the periphery, CD39 is upregulated upon Treg activation and acts 
with CD73 to convert ATP into the immunosuppressive molecule adenosine [249-252]. CD127 
is downregulated on Tregs and is inversely related to Treg immunosuppressive capacity [21, 
379]. CD39+ Tregs were most abundant in MSP6 population and were likely the CD39+ Tregs 
detected in the CD4+ SP thymocytes by Nunes-Cabaço et al. [63]. Nunes-Cabaço et al. reported 
lower expression of CD127 of FOXP3 CD4+ SP thymocytes compared to the corresponding 
FOXP3- population. However, while MSP1-MSP5 Tregs had relatively low expression of 
CD127, we found high expression of CD127 on the MSP6 Tregs. Additionally, comparing CD39 
and CD127 expression on MSP6 revealed distinct CD39- CD127-, CD39+ CD127-, CD39+ 
CD127+ and CD39- CD127+ populations. Thus, CD39 expression on CD4+ CD3hi MSP 
thymocytes was as expected however we did not find low CD127 expression on the MSP6 
subset.  
The MSP6 subset is clearly a distinct subset of CD4+ CD3hi thymocytes compared to the 
MSP1-MSP5 populations which appear to follow a clear developmental sequence. We 
hypothesize that the MSP6 subset is made up of re-circulating T cells. These cells are CD45RO+ 
which is a memory T cell marker and indicates that these cells have been previously activated 
[144]. This previous activation could explain the distinct populations of CD39 and CD127 
expressing CD25+ FOXP3+ T cells. In humans, FOXP3 and CD25 not only define CD4+ Tregs 
but can also be transiently upregulated by Tconvs [133, 199, 200]. Thus, the CD25+ FOXP3+ 
that express the expected CD39 and CD127 expression pattern, CD39+ CD127-/lo or CD39- 
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CD127-/lo are likely the true Tregs and the CD39+ C127+ and CD39 and CD127- MSP6 CD25+ 
FOXP3+ could be activated CD4+ T cells or peripherally induced Tregs that do not have a 
complete Treg phenotype. They are likely peripherally induced Tregs as these cells make up a 
large proportion of cells that are defined as Tregs in thymic Treg studies and these cells are able 
to suppress in vivo and in vitro. Further functional studies and analysis of Treg markers are 
required to determine the nature of this diverse MSP6 population that has a high percentage of 
FOXP3 CD25+ T cells.  
In conclusion, Treg development can be traced through the novel CD4+ MSP1-MSP5 
populations that we recently defined. Helios and Eos upregulation during the MSP3 stage likely 
increases FOXP3 and CD25 expression and drives Treg development in the MSP stages. CD4+ 
CD25+ FOXP3+ Tregs isolated from the thymus are predominantly in the MSP6 subset and it 





Chapter 4 : Treatment of Graft Versus Host Disease with Wharton’s Jelly Mesenchymal 
Stem Cells 
Abstract 
The objective of this study was to determine if Wharton’s Jelly Mesenchymal Stem Cells 
(WJMSC) could effectively prevent disease in a xenogeneic murine graft versus host disease 
(xenoGVHD) model. In the xenoGVHD model, mice were injected with human peripheral blood 
mononuclear cells (PBMC) alone or with varying doses of WJMSC. Upon reaching an endpoint 
disease score, mice were euthanized. T cells were then isolated from spleens and analyzed via 
flow cytometry. Results from this study demonstrated that administration of fewer than 2x106 
WJMSC can be safely administered to mice via retroorbital injection.  In addition, treatment of 
xenoGVHD mice with of ≥106 WJMSC improved survival in and delayed disease progression.  
Further, administration of ≥106 WJMSC increased percent of effector T cells and reduced 
percent of naïve T cells isolated from xenoGVHD mouse spleens. In conclusion, these data 
suggest that there is potential for utilization of WJMSC as graft versus host disease (GVHD) 
prophylaxis. This study was not conducted in compliance with Good Laboratory Practice (GLP) 





Graft versus host disease (GVHD) is a common complication in allogeneic hematopoietic 
stem cell transplant (HSCT) that results in about 15-30% of the deaths following 
transplantation[300]. GVHD manifests when donor immune cells, primarily T cells, attack 
recipient organs. Current GVHD treatments are insufficient, with only about 50% of patients 
experiencing a sustained response[304]. Mesenchymal stem cells (MSC) from human bone 
marrow have been investigated as treatment of GVHD with promising results[380]. However, 
bone marrow-derived MSCs are painful to collect and are difficult to expand to therapeutic 
doses[380]. MSCs can also be isolated from Wharton’s Jelly, the embryonic mucosal tissue 
between the amniotic epithelium and the umbilical vessels, and these MSCs are able to 
proliferate at a higher rate than bone marrow derived MSCs[381, 382]. The efficacy of 
Wharton’s Jelly mesenchymal stem cells (WJMSC) at treating GVHD has yet to be determined. 







Isolation of Wharton’s Jelly Mesenchymal Stem Cells  
WJMSC were isolated from human umbilical cord segments following an Investigational 
Review Board-approved informed consent process.  The tissue was thoroughly washed with PBS 
containing antibiotics to remove traces of blood and minimize potential bacterial contamination.  
The 2 arteries and 1 vein were removed and a final phosphate buffered saline (PBS) wash was  
conducted.  The tissue was then minced into 2-3mm pieces and incubated in xeno-free, serum-
free media, to allow the cells to migrate out of the tissue and attach to the tissue culture dish.  
Explanted cells were  then expanded through a total of 5 passages to generate approximately 2 x 
106 WJMSC for in vivo and in vitro studies. 
Recovered cells from passage 5 were centrifuged and resuspended at a concentration of 6 
x 106 WJMSC/mL in 70% Plasmalyte A, 5% human serum albumin (has) and 10% 
dimethylsulfoxide (DMSO) (v/v) then frozen using a controlled rate freezer to assure 
consistency.  Long-term storage was at ≤ -150°C. For administration, cells were removed from 
liquid nitrogen storage and placed at 37°C with intermittent gentle agitation until the cell 
suspension was fully thawed.  The cells were then gently mixed and can be stored at 4°C for up 
to 6 hours prior to administration. 
Isolation of Human Peripheral Blood Mononuclear Cells (PBMC)  
Blood was collected from five healthy adult volunteer donors under signed informed consent 
with approval from the Institutional Review Board of the University of Kansas Medical Center. 
Blood was collected in heparin tubes and PBMC were isolated via Ficoll-Paque (GE Healthcare 
[United Kingdom]) density centrifugation with SepMate tubes (STEMCELL Technologies Inc. 
[Vancouver, BC]). PBMC were always used fresh and never frozen. 
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Mice and Xenogeneic Murine GVHD Model  
All animal studies were performed in compliance with the U.S. Department of Health and 
Human Services Guide for the Care and Use of Laboratory Animals. NOD-SCID IL-2Rγnull 
(NSG) mice were purchased from Jackson Laboratories and bred at the University of Kansas 
Medical Center.  Mice were maintained under specific pathogen-free conditions using sterile 
food, water, bedding, and caging. NSG mice (8-12 weeks old) received 1.5 Gy of whole body 
irradiation. The next day, the mice were anesthetized via 2% inhaled isoflurane and injected 
retro-orbitally with 107 human PBMC alone or with one of the following doses of WJMSC: 107, 
2x106, 1.5x106, 1x106, 5x105, 1.25x105, 3.125 x104. Cells were re-suspended in 100 ul of sterile 
PBS (Thermo Fischer [Waltham, MA]). Mice were examined for signs of GVHD, using the 
following GVHD scoring system[310]. Five categories were assessed on a scale of 0, 1, or 2 for 
each. Weight loss: 0= <10% change, 1= 10-25% change, 2= >25% change, Posture: 0= normal, 
1= hunching at rest, 2=hunching impairs movement, Fur texture: 0= normal, 1= mild to moderate 
ruffling, 2= severe ruffling, Skin integrity: 0=normal, 1=scaling of paws/tail, 2= obvious areas of 
denuded skin, Activity: 0=normal, 1=mild to moderately decreased, 2=stationary unless 
stimulated. Mice were sacrificed when they reach a GVHD score of ≥6 or live longer than 42 
days. The researcher assessing score was blinded to the treatment of each mouse for 20 out 44 
mice assessed.  
 
Flow Cytometry 
Spleens from mice were processed into a single cell suspension and stained with the following 
antibodies (BioLegend [San Diego, CA])): anti-human CD3 APC-Cy7, anti-human CD4 Pacific 
Blue, anti-human CD8 Brilliant Violet 785, anti-human CD25 PerCPCy5.5, anti-human CD127 
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Brilliant Violet 650, anti-human CCR-7 PE-Cy7, anti-human CD45RA Alexa Fluor 700. 
Samples were run on a Becton-Dickson LSRII (Becton-Dickson [Franklin Lakes, NJ])). 
Data/Statistical Analysis 
Data is stored on a secure server at the University of Kansas Medical Center. Data was collected 
and analyzed with GraphPad Prism 6 (GraphPad Software, [La Jolla, CA]).  Data reported at 
each time point for GVHD score and weight loss were an average of the scores and weights of 
the mice left alive and the last scores and weights of any deceased mice in each group. Two-way 
ANOVA was done to compare GVHD scores and weight loss at various time points. The log-
rank (Mantel-Cox) test was used for analysis of Kaplan-Meier curves. Differences between two 
groups with unmatched data were compared using an unpaired t-test.  p≤0.05 was considered to 





Administration of fewer than 2x106 WJMSC to mice is safe.  
To identify the maximum number of cells we can safely inject into mice, mice were injected with 
107 PBMC and varying numbers of WJMSC, as shown in Table 4-1. All mice injected with 107 
WJMSC died immediately after administration. Additionally, two out of three mice receiving 
2x106 WJMSC died immediately.  All mice that received fewer than 2x106 survived the injection 
of cells. Thus, administration of fewer than 2x106 WJMSC to mice via retro-orbital injection is 
safe. 
Administration of 106 WJMSC or greater improved survival and delayed GVHD disease 
progression in a xenoGVHD model.  
To test the immunosuppressive capacity of WJMSC in vivo, the same mice described in Table 1 
were evaluated for GVHD onset and progression. Each group of mice receiving WJMSC was 
compared to the control mice receiving PBMC alone.  None of the groups were statistically 
different.  However, the comparison of GVHD scores between mice receiving 106 WJMSC and 
the control group resulted in a probability of the two lines being identical being less than 20% 
(Data not shown).  By contrast, the GVHD scores between mice receiving 5x105 and control 
mice were nearly identical (p=0.62, data not shown).  Based on this difference, the data were 
reanalyzed by combining groups of mice that received ≥106 WJMSC and mice that received <106 
WJMSC and comparing them to mice that received PBMCs alone.  Of the mice that survived 
initial injection of WJMSC, dosing ≥106 WJMSC significantly improved survival with median 
survival time equal to 30 ± days compared to 23± days for PBMCs alone (p= 0.0417) and 20 ± 
days for <106 WJMSC, (Fig. 4-1A). Administration of doses ≥106 WJMSC also significantly 
delayed GVHD disease progression (p= 0.0194) and decreased weight loss over time (p=0.1108) 
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compared to PBMCs alone. <106 WJMSC did not significantly change GVHD score (p=0.5249) 
or weight loss (p=0.5393) compared to PBMCs alone. (Figs. 4-1B and 4-1C).  These data 
suggest that administration of ≥106 WJMSC can improve survival and reduce disease in a 
xenoGVHD model.  
Administration of 106 WJMSC or greater increased percent of effector T cells and reduced 
percent of naïve T cells isolated from xenoGVHD mouse spleens.  
To determine the potential mechanism of immunosuppression by WJMSC, cells were isolated 
from spleens of euthanized mice that had reached a GVHD score of 6 or greater and phenotype 
was analyzed via flow cytometry. The percentage of CD4+ T cells that were effector memory T 
cells, defined as CCR7-CD45RA-, trended higher in mice that received 106 WJMSC compared 
to mice that received PBMCs only; 40.98% ± 11.4% (n=9) versus 32.63% ± 19,6% (n=9) (p=0. 
0.0560, Fig. 4-2A). The percentage of effector memory CD8+ T cells trended higher in mice that 
received 106 WJMSC compared to PBMCs alone; 28.43% ± 5.8% (n=9) versus 23.25% ± 
15.1% (n=4) (p=0.2186, Fig. 4-2B). Interestingly, this population of effector memory CD8+ T 
cells was significantly increased in mice that received <106 WJMSC compared to PBMCs alone; 
40.54% ± 12.36% (n=7) (p=0.0001, Fig. 4-2B). The percentages CD4+ T cells that were 
regulatory T cells (Tregs), defined as CD4+ CD25hi CD127lo, were nearly identical between the 
three  groups; 4.81% ± 4.98% (n=9) of CD4+ T cells from mice receiving 106 WJMSC, 5,27% 
± 5.4% of CD4+ T cells from mice receiving <106 WJMSC (n=7) and 3.9% ± 2.7% (n=4) of 
CD4+ T cells from mice receiving PBMCs only  (Fig. 4-2A). Thus, administration of 106 
WJMSC mediated an increase in the percent of effector CD4+ T cells and any dose of WJMSC 
caused an increase in effector memory CD8+ T cells. 
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Table 4-1: WJMSC dosage and survival of mice 
  Table 1:  WJMSC Dosage 
  
# of 
WJMSC # of PBMC # of mice 
# of mice that survived 
initial injection 
  0 10
7
 7 7 










































Figure 4-1: Administration of 106 WJMSCs or greater improved survival in and delayed 
GVHD disease progression in a xenoGVHD model. 8-12 week-old NSG mice were sub-
lethally irradiated. The next day, the mice were injected retro-orbitally with 107 human PBMCs 
alone or with the doses of WJMSC listed in table 1.  Mice that survived injection from 4 separate 
experiments were pooled into three groups: PBMCs alone (n=7), PBMCs+ <106 WJMSCs 
(n=13) and PBMCs+ 106 WJMSCs (n=11). A) Kaplan-Meier curve of survival; log-rank test 
was performed. Death was marked when GVHD score was 6. B) GVHD score and C) weight 
loss were monitored until day of sacrifice.  *Curves were significantly different between PBMCs 








Figure 4-2: Administration of 106 WJMSCs or greater increased percent of effector T 
cells and reduced percent of naïve T cells isolated from xenoGVHD mouse spleens. Spleens 
from euthanized mice were processed into a single cell suspension and analyzed via flow 
cytometry.  The mean and standard deviation of the percentages of CD4+ T cell subsets (A) and 
CD8+ T cell subsets (B) from mice receiving PBMCs only (n=4), PBMCs± <106 WJMSCs (n=7) 





Figure 4-2: Administration of 106 WJMSCs or greater increased percent of effector T cells and reduced percent of 





In this small pilot study, we demonstrated that WJMSC can delay GVHD disease 
progression and improve survival in a xenogeneic murine GVHD model. Furthermore, this is the 
first study to analyze the phenotype of human T cells isolated from xenoGVHD mice that have 
been treated with WJMSC. There was an increase in the proportion of T cells that were effector 
cells in mice treated with ≥106 WJMSC.  
Injection ≥2x106 WJMSC may be lethal to mice because these cells have been shown to 
occlude vasculature and can cause pulmonary emboli leading to immediate death[383]. We 
administered the PBMC and WJMSC via retro-orbital injection which leads to more rapid 
distribution of cells than intravenous injection via tail vein. This increase in infusion rate leads to 
increased risk of pulmonary emboli, explaining the increased frequency of immediate death 
observed in this study. Our data indicate that no mortality was observed at WJMSC doses below 
2 x 106 cells. 
It was expected that WJMSC delay disease in a xenoGVHD model given the ability of 
WJMSC to suppress T cell proliferation in vitro [384]. Furthermore, WJMSC have been shown 
to attenuate disease in a murine model of asthma, a murine model of colitis and a rat model of 
autoimmune encephalitis[385-387]. Though the WJMSC did not entirely prevent disease, there 
was a delay in disease progression as measured by survival, GVHD score and rate of weight loss. 
Of these parameters, GVHD score and survival reached statistical significance. Additionally, the 
WJMSC were not primed as described in Polchert et al. [388]; priming may have resulted in 
improved outcome. Overall, these data demonstrate that there is potential for utilization of 
WJMSC as GVHD prophylaxis. 
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The increase in effector memory CD4+ and CD8+ T cells in xenoGVHD mice treated with 
<106 and ≥106 WJMSC was unexpected. Given the immunosuppressive properties of WJMSC in 
vitro[384], we hypothesized that there would be reduced differentiation of T cells when co-
injected with WJMSC in vivo. However, T cell phenotype after co-culture with WJMSC has not 
been studied extensively, thus it is not clear how T cells respond to WJMSC in vivo. It is difficult 
to define the exact mechanism of WJMSC-mediated immunosuppression in this experiment as 
cells were analyzed when animals reached the endpoint of disease. It is possible that WJMSC 
may have allowed animals to live long enough for T cells to differentiate explaining the increase 
in effector memory T cells in the ≥106 WJMSC group versus the <106 WJMSC group. Future 
experiments will be needed to analyze cells from treatment and control groups at the same time 
point in the middle of disease progression to gain a better idea of how WJMSC alter PBMC-
mediate disease progression versus PBMC alone. We have demonstrated that ≥106 WJMSC 
correlates with an increase in effector memory T cell ratio in a xenoGVHD model compared to 
PBMCs alone.  
In conclusion, these data demonstrate that administration of fewer than 2x106 WJMSC is 
safe.  In addition, treatment of xenoGVHD mice with of ≥106 WJMSC improved survival in and 
delayed GVHD disease progression.  Further, administration of ≥106 WJMSC increased percent 




Chapter 5 : Conclusions 
 This work provides further insight into the role of Ikaros family members in human Treg 
function and development. In Chapter II, we co-expressed FOXP3 with Hel-FL or with Hel-Δ3B 
in total human T cells to generate eTregs. We demonstrated that co-expression of FOXP3 and 
Hel-FL is not only able to improve CD4+ eTreg function, but also generate CD8+ eTregs 
compared to FOXP3 alone. Furthermore, we showed that Hel-Δ3B co-expression with FOXP3 
doesn’t change CD4+ eTreg function but improves CD8+ eTregs suppression compared to 
FOXP3 alone. This work not only improves existing eTreg technology, it offers a more detailed 
look at the role of Helios and its endogenous splice variants in mediating T cell 
immunosuppression. In Chapter III, we used multiparameter flow cytometry to trace Treg 
development in the human thymus and describe changes in the Ikaros family members and Treg 
markers during this development. Using subsets of CD4+ MSP populations we previously 
defined [77], we were able to determine which population contained the highest percentage of 
CD4+ CD25+ FOXP3+ Tregs. We then defined Ikaros protein expression and Treg marker 
expression within Tregs from these populations. Interestingly, the small MSP6 population, which 
did not fit normal CD4+ T cell development, contained the highest number of Tregs which had 
subpopulations based on Ikaros family and Treg marker expression. These data provide 
additional detail to human Treg development and the thymic Treg phenotype in general. Overall, 
these studies highlight the critical roles that the Ikaros family of transcription members in Treg 
function and development and emphasize the need the further studies to fully characterize the 




Dual expression of FOXP3 and Hel-FL in human total T cells conveys immunosuppressive 
function 
With the discovery of Tregs, there has been much effort to utilize Tregs as a cellular 
therapy for inflammatory diseases such as GVHD, transplant rejection and type I diabetes [35-
39]. Barriers to adoptive Treg transfer include difficulties in generating sufficient numbers to 
treat, obtaining pure populations and survival of Tregs in vitro.  To overcome these limitations, 
there have been attempts to artificially generate Tregs by ectopically expressing FOXP3 in both 
mouse and human CD4+ Tconv [14, 32, 255]; we have termed these cells “engineered Tregs” or 
“eTregs.” FOXP3 eTregs express Treg markers, suppress T cell proliferation in vivo and in vitro 
[14, 32, 255]. However, when directly compared to endogenous Tregs, FOXP3 eTregs are not as 
effective at suppressing and do not completely recapitulate Treg immunosuppressive capacity 
[296]. This is expected as RNA Sequencing of FOXP3 transduced murine CD4+ Tconvs 
revealed that FOXP3+ expression does not completely convey the Treg gene signature [277]. 
The same study demonstrated that ectopic expression of Helios, another Treg transcription 
factor, regulated different Treg genes compared to FOXP3 [277]. Furthermore, Helios+ Tregs in 
humans have improved stability of the Treg phenotype under inflammatory conditions compared 
to Helios- Tregs [9, 20, 21].  Thus, we hypothesized that the addition of Helios to FOXP3 in 
eTregs would improve the immunosuppressive capacity of eTregs both in vivo and in vitro.  
We incorporated many novel aspects into our generation of eTregs. First, we chose to 
retrovirally transduce both CD4+ and CD8+ human T cells, whereas existing eTreg work has 
only transduced CD4+ T cells. We decided to include CD8+ T cells because Helios has been 
implicated as a critical mediator of CD8+ Treg function [43, 191]. Additionally, removing the 
CD4+ purification step would facilitate translation of this process into the clinic.  Second, we 
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implemented a two-step transduction protocol, as Helios downregulated expression of 
transduction markers and cDNA on the same plasmid in about four days with our retroviral 
transduction system. Finally, we investigated the role of the shorter Hel-Δ3B isoform of Helios 
in addition to the full length Hel-FL isoform to determine if there were any functional 
differences between these two splice variants. 
Our work revealed that FOXP3+Hel-FL eTregs had the most robust immunosuppressive 
ability both in vivo and in vitro. In the xenoGVHD model, FOXP3+Hel-FL eTregs were the only 
cells that were able to significantly delay disease. In vitro, both CD4+ and CD8+ FOXP3+Hel-
FL eTregs had increased suppression compared to FOXP3 eTregs. In comparing FOXP3 and 
FOXP3+Hel-FL eTregs, the increased immunosuppression by FOXP3+Hel-FL eTregs can be 
correlated with gene expression changes in KEGG pathways and Treg transcriptional signature 
in both CD4+ and CD8+ cells. These genes need to be further investigated as potential mediators 
of T cell suppressive activity. Additionally, we know that the effects of Helios we observed are 
independent of its effects on FOXP3 transcription because FOXP3 is overexpressed in these 
cells. Thus, additional work is required to determine what downstream signals are affected by 
Helios and FOXP3 co-expression and how these signals mediate improved eTreg function. These 
results improve our understanding of Helios in Treg function.  
 
Functional differences between endogenous splice variants of Helios  
 Little is known about the roles of the two Helios splice variants expressed in human T 
cells. Hel-Δ3B is lacking half of exon 3 which would affect its DNA-binding domain [40]. Hel-
FL and Hel-Δ3B have been overexpressed in 293T HEK T cells or COS7 cells to assess 
suppression of transcription via a Hes1 promoter-driven luciferase assay [40, 389]. Hes1 contains 
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Helios DNA binding domains. These assays yielded conflicting results as both demonstrated that 
Hel-FL suppressed Hes1 promoter activity but one study found that Hel-Δ3B did not suppress 
activity [40] and the other found Hel-Δ3B suppressed activity as well as Hel-FL[389]. These 
discrepancies may be due to differences in the cell lines used and they do indicate a potential 
difference in Hel-FL and Hel-Δ3B transcriptional activity. In regards to the differences in these 
Helios isoforms in T cells, only Hel-FL has been studied in Jurkat cells, a human T cell line, and 
there have not been any studies in primary human T cells. Ectopic of Hel-FL in Jurkats by Getnet 
et al. resulted in increased apoptosis and they concluded that Helios alone was insufficient to 
convey Treg properties [44].  
Given the lack of data comparing Hel-FL to Hel-Δ3B, it was unexpected that FOXP3+ 
Hel-Δ3B eTregs did not perform equally as well as FOXP3+Hel-FL eTregs in vivo. In vitro, 
FOXP3+Hel-FL and FOXP3+Hel-Δ3B eTregs were similar in proliferation, survival, Treg 
marker expression and cytokine secretion. Despite these similarities, FOXP3+Hel-FL and 
FOXP3+Hel-Δ3B eTregs did differ in in vitro suppression of T cell proliferation. FOXP3+Hel-
FL CD4+ eTregs had improved suppression compared to CD4+ FOXP3+Hel-Δ3B eTregs. 
Interestingly, FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD8+ eTregs had similar suppressive 
capacity and both were better than FOXP3 only CD8+ eTregs. These data not only demonstrated 
a functional difference between Hel-FL and Hel-Δ3B, but this difference was specific to CD4+ T 
cells. RNA Sequencing data revealed that FOXP3+Hel-FL CD4+ eTregs had differences in gene 
transcription of KEGG pathways and Treg-related genes compared to FOXP3+Hel-Δ3B CD4+ 
eTregs. Specifically, p53 signaling was significantly downregulated in FOXP3+Hel-Δ3B CD4+ 
eTregs (Figure 2-10B) and p53 has been demonstrated to be critical in CD4+ Treg induction in 
mice [348]. Additionally, chemokine receptors were upregulated in the cytokine-cytokine 
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receptor interaction pathway for FOXP3-Hel-FL CD4+ eTregs (Figure 2-10B) which could 
mediate increased migration to sites of inflammation.  In regards to the Treg signature genes, 
based on functional data, it is likely that gene differences that were unique to the FOXP3+Hel-
FL vs FOXP3 or FOXP3+Hel-Δ3B vs FOXP3 comparisons are key mediators of T cell 
suppression. There were also changes in KEGG pathways and Treg signature genes when 
comparing FOXP3+Hel-FL and FOXP3+Hel-Δ3B CD8+ eTregs. However, based on the 
function of these eTregs, these changes may not be as critical in mediating CD8+ T cell 
immunosuppressive function. Overall, these data have shown that Hel-FL and Hel-Δ3B co-
expression with FOXP3 differentially mediate immunosuppression in human CD4+ and CD8+ T 
cells and these differences may be due to changes in downstream gene expression. Whether these 
transcriptional changes are directly due to Helios activity or indirectly due to Helios interaction 
with other proteins requires further research.  
Correlating the functional and transcriptional differences between FOXP3+Hel-FL 
eTregs and FOXP3+Hel-Δ3B eTregs can provide abundant information about T cell-mediated 
immunosuppression. It is unclear why FOXP3+Hel-FL eTregs were more effective in vivo than 
FOXP3+Hel-Δ3B eTregs. One reason could be a larger of number of eTregs were present in 
mice treated with FOXP3+Hel-FL eTregs because both CD4+ and CD8+ Tregs were highly 
suppressive whereas there were only suppressive CD8+ eTregs present in FOXP3+Hel-Δ3B 
eTregs treated mice. Another possibility is CD8+ eTregs might be insufficient to delay disease in 
a xenoGVHD model. Thus, further investigation of the differences between FOXP3+Hel-FL 
eTregs and FOXP3+Hel-Δ3B eTregs will not only determine differences in downstream gene 
signaling but differences in CD4+ and CD8+ eTreg function and requirements for preventing 
disease in the xenoGVHD model.  
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Expression of Ikaros family members during CD4+ Treg development through CD4+ 
MSP1 to MSP5 stages 
Treg development in humans has been difficult to characterize due to limitations of in 
vitro assays and many differences between murine and human T cell development. Thus far, it 
has been determined that TCR stimulation of FOXP3+ DP thymocytes, followed by stimulation 
by IL-2 and IL-15 is one pathway to Treg lineage commitment [63, 70, 72]. Additionally, 
FOXP3 and CD25 expression can be induced in mature FOXP3- CD25- CD4+ SP through a 
combination of TCR engagement, IL-2 and IL-15 stimulation and co-stimulation [69, 72, 74, 75]. 
When Treg lineage occurs during the different stages of T cell development has been determined 
by tracing CD4+ CD25+ FOXP3+ T cells. Human Treg lineage commitment can occur at CD4+ 
CD8+ double positive (DP) or the CD4+ single positive (SP) developmental stages [56]. FOXP3+ 
CD4+ SP tTregs or FOXP3+ CD8+ SP tTregs can develop from FOXP3+ DP thymocytes.  
Our work provides more details on the path that thymocytes follow to Treg lineage 
commitment by examining the novel CD4+ MSP1-MSP5 subsets of T cell development 
previously defined by our laboratory [77] as well as investigating a new MSP6 subset. Upon 
determining the frequency of CD4+ CD25+ FOXP3+ within the CD4+ MSP1-MSP5 subsets, we 
found that the MSP3-MSP5 cells had the highest frequency of Tregs. Interestingly, there was an 
increase in Helios and Eos in these Tregs at the MSP3 stage. These two members of the Ikaros 
family are critical for induction of FOXP3 and CD25 and Treg function [43, 285]. Thus, their 
upregulation and increase in Treg frequency in the MSP population are likely correlated and 
indicate a role in these two factors in Treg commitment and development in the thymus. 
Functional assays in the future will be required to determine the maturity of the these developing 
Tregs and if relative expression of Ikaros proteins affects their activity. Overall, examining 
123 
 
Ikaros family members in relation to Treg abundance at different stages at Treg development 
could help precisely define points of Treg commitment.  
 
CD4+ MSP6 thymocytes represent a high percentage of CD4+ CD3hi CD25+ FOXP3+ 
Tregs in the human thymus 
 When the CD4+ MSP1-MSP5 populations were defined, a small subset of CD4+ CD3hi 
CD38lo CD45RO+ cells, referred to as MSP6, were excluded from the developmental sequence 
because their expression of CD38 and CD45RO did not correlate with mature thymocytes. 
However, when we analyzed these cells for the presence of CD4+ CD25+ FOXP3+ Tregs, we 
were surprised to find that approximately 50% of MSP6 cells were Tregs. Upon further 
evaluation of Ikaros family members and the Treg markers, CD39 and CD127, we hypothesized 
that these Tregs were likely re-circulating Tregs from the periphery. Within this population, the 
certain subsets express markers that are consistent with thymic Tregs such as Helios+, CD127lo, 
CD39+. However, other subsets express combinations of these markers that would not be 
expected in thymic Tregs. Thus, it is likely that some of these Tregs are FOXP3- Tconvs that 
were peripherally induced to express FOXP3 or pTregs. pTregs lack the epigenetic modifications 
present in tTregs and thus do not always have the same marker expression as tTregs [198]. These 
are likely pTregs and not activated Tconvs that transiently upregulated FOXP3 and CD25 
because studies have shown that the CD4+ CD25+ FOXP3+ cells isolated from human thymus 
are able to suppress and majority of these cells would come from the MSP6 population [289]. In 
conclusion, within our novel T cell development subsets, we identified markers that could help 
identify re-circulating Tregs in the thymus. Further functional and phenotypical analysis of these 
Tregs will be required to support this hypothesis.  
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Significance and Future Directions 
 The results from these studies clarify the roles of the Ikaros family of transcription factors 
in Treg biology and provide information that can further Treg immunotherapy. We are the first to 
describe a method that co-expresses both FOXP3 and Hel-FL in human total T cells and 
effectively mediates immunosuppression by both CD4+ and CD8+ T cells. Future work can be 
done to determine if survival of these cells could be improved or if multiple dosages would 
improve delay of GVHD. Furthermore, these eTregs could be tested in the treatment of other 
inflammatory diseases such as diabetes or transplant rejection. In addition to a novel eTreg 
protocol, our RNA Sequencing data provides the first transcriptional profile of CD4+ and CD8+ 
human T cells ectopically expressing both FOXP3 and Helios. Further evaluation of the 
transcriptional changes between these cells can provide a more detailed look into the role of 
Helios in mediating immunosuppression with FOXP3 in both CD4+ and CD8+ T cells. We are 
also the first group to describe a functional difference between the endogenous Helios splice 
variants Hel-FL and Hel-Δ3B in primary human T cells. Given the differences we see in 
overexpressing these Helios isoforms, it would be interesting to define the endogenous splicing 
of Helios in different Treg and T cell subsets in both healthy patients and disease states. Finally, 
the expression profiling of Ikaros family members in Tregs found in the CD4+ MSP1-MSP5 
populations may have defined a more precise stage of Treg lineage commitment.  Similar studies 
could be applied to earlier stages of T cell development to determine other points of Treg 
commitment. Additionally, phenotyping of Tregs found in the MSP6 population could have 
revealed new markers for re-circulating Tregs in the thymus and provided more details on thymic 
Tregs that are currently being used in clinical trials [390]. Overall, the data from this work will 
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significantly impact studies investigating the Ikaros family in Treg-mediated immunosuppression 
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